COMMUNICATION

WILEY-VCH

Three-Component Reaction for the Synthesis of Highly Functionalized Propargyl Ethers

Guillaume Pisella, Alec Gagnebin and Jérôme Waser*

Abstract: Multicomponent reactions provide efficient means to access molecular complexity. Herein, we report a copper-catalyzed three-component reaction of diazo compounds, alcohols and ethynyl benziodoxole (EBX) reagents for the synthesis of propargyl ethers. Extensive variations of the three partners of the reaction is possible, leading to highly functionalized and structurally diverse products under mild conditions. Alkynylation of a copper ylide intermediate is postulated as key step for this transformation.

Multicomponent reactions are ideally suited for a fast entry into molecular complexity.^[1] It is therefore not surprising that classical multicomponent reactions such as the Ugi or the Passerini reactions have had a major impact on both synthetic and medicinal chemistry.^[2] Recently, diazo compounds have emerged as ideal partners in multicomponent reactions, with or without the help of transition metal catalysts.^[3] In particular, transient ylide intermediates generated from the insertion of protic nucleophiles (alcohols, amines, thiols and aromatic compounds) into metalcarbenes generated from diazo compounds have been intercepted with various electrophiles (carbonyl compounds, imines, Michael acceptors, azodicarboxylates, electrophilic halogen sources,...) to simultaneously generate two new bonds (Scheme 1A).^[4] To further develop the use of this strategy in multicomponent reactions, it is now important to extend the scope of compatible nucleophiles/electrophiles for achieving a higher molecular diversity.


In this context, hypervalent iodine reagents in general $\ensuremath{^{[5]}}$ and cyclic derivatives in particular^[6] have demonstrated their versatility for the Umpolung of the reactivity of functional groups, giving access to a broad range of non-classical electrophiles. However, their use in multi-component reactions involving diazo compounds is not yet well established. In the absence of a metal-catalyst, Murphy and co-workers have first reported dihalogenation reactions.^[7] More recent examples involve acetoxyaminoalkylation^[8] and azidoaminoalkylation.^[9] The first transformations involving metal carbene intermediates were reported independently by our group^[10] and Szabo and co-workers.^[11] We developed a coppercatalyzed oxy-alkynylation using ethynylbenziodoxolone (EBX) reagents, whereas Szabo and co-workers successfully implemented a rhodium-catalyzed oxy-fluoro/trifluoromethylation with benziodoxole reagents (Scheme 1B). These two transformations constitute efficient multi-bond forming reactions combining hypervalent iodine reagents and diazo compounds and most probably proceed via ylide intermediates generated from metal carbenes. Nevertheless, they remain strongly limited in the diversity of structures accessible: our work allowed exclusively the introduction of iodo-benzoate derivatives as nucleophilic

 [*] G. Pisella, A. Gagnebin, Prof. Dr. J. Waser Laboratory of Catalysis and Organic Synthesis, Ecole Polytechnique Fédérale de Lausanne, EPFL, SB ISIC LCSO, BCH 4306 1015 Lausanne (Switzerland) Email: jerome.waser@epfl.ch Homepage : http://lcso.epfl.ch/

Supporting information for this article is given via a link at the end of the document.

partners in the three-component reaction, whereas the work of Szabo-and co-workers was limited to fluoride or trifluoromethyl as one of the partners. Therefore, there is an urgent need for more general three-component reactions of diazo compounds, nucleophiles and hypervalent iodine reagents, allowing for extensive variation of the three partners with diverse functional groups in order to maximize the structural diversity of the products.

Herein, we report the copper-catalyzed three-component reaction of diazo compounds, ethynylbenziodoxoles (EBXs) and alcohols, which overcomes this limitation (Scheme 1C). The three components of the reaction can be extensively varied, leading to a broad range of important propargylic ether building blocks with high structural diversity.^[12] In particular, primary, secondary and tertiary alcohols, as well as a broad range of functional groups (including alkene, alkyne, fluoro, chloro, bromo, ether, ester, ketone, carbamate, imide, cyano, boronic ester and heterocyclic groups) were well tolerated, which would be difficult to achieve using traditional etherification methods under strongly basic or acidic conditions. The transformation can be performed using simple copper salts as catalyst, and does not require the use of one of the partners in large excess.



Scheme 1. Multi-component reactions of diazo compounds involving ylide intermediates and new disconnections enabled by hypervalent iodine reagents.

We first investigated the three-component reaction of TIPS-EBX (1), ethyl diazoacetate (**3a**) and ethanol (**4a**) (Table 1). In our previous work on the two-component process, diimine an bisoxazoline ligands on the copper catalyst led to best results.^[10] Using Cu(MeCN)₄BF₄ as catalyst, diimine **8** or *tert*-butyl bisoxazoline (*t*Bu-BOX (**9**)) as ligands and ethanol as solvent, the desired product **5a** could be obtained in 50% and 63% yield, respectively (entries 1 and 2). However, despite using ethanol as solvent, a significant amount (30-32%) of the two-component product **7a** was still obtained. Furthermore, when only 10

COMMUNICATION


equivalents of ethanol were used, the yield of **6a** dropped to 22% (entry 3), showing that these conditions would not be useful to develop a general three-component reaction.

Table 1. Optimization of the three-component reaction

| $\begin{array}{c} O \\ X \\ X \\ X \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$ | $\begin{array}{c} N_2 \text{ (2 equiv.)} \\ H 3a \\ \hline D_2 \text{ EtOH (4a)} \end{array} \xrightarrow{\text{EtO}} H \end{array}$ | Si/Pr ₃ EtO H CO ₂ Et ⁺ H | D ₂ Et + O H CO ₂ Et |
|--|--|--|--|
| ~ | Cu cat., CD ₂ Cl ₂ 5 | | 7a |

| Entry | EBX | Equiv EtOH (4a) | Catalyst/Ligand(additive) | Yield 5a/6a/7a [%] ^[a] |
|-------------------|-----|-----------------------------|---|---|
| 1 | 1 | as solvent | 4 mol% Cu(MeCN) ₄ BF ₄ /8 | 50/n.d./32 |
| 2 | 1 | as solvent | 4 mol% Cu(MeCN)4BF4/9 | 63/n.d./30 |
| 3 | 1 | 10 | 4 mol% Cu(MeCN)4BF4/ 9 | 22/n.d./52 |
| 4 | 2a | as solvent | 4 mol% Cu(MeCN)4BF4/9 | 62/n.d./- |
| 5 | 2a | as solvent | 4 mol% Cu(MeCN) ₄ BF ₄ | 100/48/- |
| 6 | 2a | 10 | 4 mol% Cu(MeCN) ₄ BF ₄ | 100/47/- |
| 7 | 2a | 4 | 4 mol% Cu(MeCN) ₄ BF ₄ | 80/49/- |
| 8 | 2a | 2 | 4 mol% Cu(MeCN) ₄ BF ₄ | 53/51/- |
| 9 | 2a | 2 | 10 mol% Cu(MeCN) ₄ BF ₄ | 62/38/- |
| 10 | 2a | 2 | 10 mol% Cu(MeCN) ₄ PF ₆ | 74/18/- |
| 11 | 2a | 2 | 10 mol% CuOTf-toluene | 60/33/- |
| 12 | 2a | 2 | 10 mol% CuOTf ₂ | 47/11/- |
| 13 | 2a | 2 | 10 mol% CuBr | 16/24/- |
| 14 | 2a | 2 | 10 mol% CuCl ₂ | 30/17/- |
| 15 | 2a | 2 | 10 mol% CuTC | 10/40/- |
| 16 ^[b] | 2a | 2 | 10 mol% Cu(MeCN) ₄ BF ₄ /NaHCO ₃ | 50/36/- |
| 17 | 2a | 4 | 10 mol% Cu(MeCN)4PF6 | 94/11/- |
| 18 ^[c] | 2a | 1 | 10 mol% Cu(MeCN) ₄ PF ₆ | 37/17/- |

^[a]Determined by ¹H NMR analysis of the crude reaction mixture. The hypervalent iodine reagent **1/2a** and the diazo compound **3a** are used as limiting reagents to calculate the yield of **5a/7a** and **6a** respectively. Reactions were run on a 0.08 mmol scale. n.d. = not determined. ^[b]With 2 equivalents of sodium bicarbonate. ^[c]One equivalent of diazo compound **3a** was used.




We therefore decided to modify the hypervalent iodine reagent. We turned to hexafluoro*iso*propanol derivative **2a**,^[13] expecting a lower nucleophilicity of the oxygen atom. Indeed, in this case only the three-component product **5a** was obtained in 62% yield (entry 4). An enhanced reactivity was observed in absence of the BOX ligand, resulting in quantitative formation of product **5a** together with O-H insertion product **6a** (entry 5). Gratifyingly, the same result was obtained when only 10 equivalents of ethanol (4a) were used (entry 6). The yield of 5a decreased to 80% and 53% respectively with 4 and 2 equivalent of ethanol (4a) (entries 7 and 8). Using a higher catalyst loading, 5a could be still obtained in 62% with only 2 equivalents of ethanol (4a) (entry 9). At this point, different copper salts were examined. Complexes with noncoordinating counterions performed better (entries 10-12) than copper halogenides (entries 13 and 14) or thiophenecarboxylate (TC, entry 15).^[14] The best result was obtained with PF₆ as counterion, giving 5a in 74% yield, with only 18% of O-H insertion product 6a formed (entry 10). We then wondered if basic condition may slow down the formation of 6a. However, a lower yield was observed in presence of sodium hydrogen carbonate (entry 16) and the reaction completely stopped in presence of other bases such as carbonate, acetate or hydroxide salts (result not shown, see Supporting Information). For cheap alcohols a larger excess is reasonable, and 5a could be obtained in 94% yield with 4 equivalents of ethanol (4a) (entry 17). Unfortunately, the formation of the alcohol insertion side product cannot be fully suppressed and it was observed for most transformations described in this study. Nevertheless, 5a was still formed in 37% yield when EBX 2a, diazo compound 3a and ethanol (4a) were used in equimolar amounts (entry 18).

With optimized conditions in hand, we started to investigate the scope of the three-component reaction. First, we employed a variety of alcohols with EBX 2a and ethyl diazo acetate 3a as the two other partners (Scheme 2A). On 0.3 mmol scale, propargylic ether 5a was isolated in 93% yield. [15] Benzyl alcohol provided the corresponding product 5b in a slightly diminished yield. Introducing a bromo substituent in the para position gave 5c in 73% yield. A heteroaromatic ring was also tolerated providing product 5d from furfuryl alcohol in 63% yield. We also examined secondary alcohols. Cyclohexanol was well tolerated and furnished the corresponding product 5e in 90% yield. We were pleased to see that the more electron-poor 1,3-difluoro-2propanol gave the desired product 5f in good yield. Sterically hindered tert-butanol still reacted remarkably well to give the corresponding three-component product 5g in 69% yield. Such tert-butyl ethers represent a synthetic challenge and are classically accessed by strong acid-catalyzed addition of isobutene to alcohols.^[16] In the case of an allyl substituent, no reaction was observed at room temperature, but at 40 °C 5h was obtained in moderate yield. A similar temperature was needed to access the bis-propargyl ether derivative 5i in 42% yield. These results may indicate a coordination of π bonds to the cationic copper catalyst.^[17] Dissociation would be needed to allow the diazo compound to coordinate and form the metal carbene, requiring a higher reaction temperature. We then examined other O-nucleophiles than alcohols. Water was a suitable partner and gave the functionalized propargylic alcohol 5i in 33% yield. However, only trace amount of the desired product was observed with acetic acid, while a complex reaction mixture was obtained with phenol.


Next, we turned our attention to more complex alcoholcontaining natural products (Scheme 2B). We were pleased to see that several terpenes such as (-)-menthol and (-)-borneol were easily functionalized and gave the corresponding threecomponent products **5k** and **5l** in very good yields. (+)-Cedrol, possessing a tertiary alcohol, was converted to **5m** in 60% yield. Geraniol was a successful nucleophile partner, providing **5n** in 57% yield, despite the presence of two potentially coordinating double bonds. Other types of natural products and biomolecules were then engaged in the three-component reaction. Notably, testosterone, protected galactose, protected thymidine and protected serine all furnished the desired propargylic ether (**5o**, **5p**, **5q** and **5r**) in moderate yields showing the breadth of the scope for alcohols.

WILEY-VCH

COMMUNICATION



versatile functional groups were tolerated on the alcohols, including a bromide (5t), a ketone (5y), protected hydroxy (5u and 5aa) or a boronic ester (5ac) groups. Several carbocyclic or heterocyclic motifs important for medicinal chemistry such as cyclopropyl (5s), cyclobutyl (5z), azetidinyl (5ab), or adamantyl (5v) were also tolerated on the alcohol. In general, the reactions occurred smoothly, affording products in good yields. By-products and a diminished yield were obtained for the synthesis of 5s, cyclopropyl alcohols being prone to ring-opening in presence of Cu(I) catalyst.^[18] The multiple unsaturations of substrate 5w could explain why only partial conversion of the EBX reagent was observed, resulting in a moderate yield.



Scheme 2. Copper(I)-catalyzed three-component reaction of alcohols with ethyl diazoacetate and TIPS-EBX. Unless otherwise noted, the reaction conditions are as follows: 2a (0.3 mmol), 3a solution in 1.0 mL DCM (0.6 mmol), 4a-r (1.2 mmol), DCM (2.0 mL). All yields refer to the isolated products. When applicable, ca. 1:1 d.r. was obtained. ^[a]Reaction conducted at 40 °C. ^[b]10.0 equiv. of water was used. ^[c]3.0 equiv. of alcohol was used.

The main strength of multi-component reactions resides in the structural diversity of accessible compounds. Therefore, we decided to simultaneously vary each of the three components of the reaction to further investigate the flexibility of our methodology, (Scheme 3). We were pleased to see that diazo esters bearing various substituents, such as alkyl (5s and 5t), aryl (5u), bulky aryl (5v) or heteroaromatic (5w) were tolerated. Diazo amides were not suitable reagents, furnishing only traces of the desired 3component products (not shown). Other diazo compounds bearing diverse versatile functionalities (nitrile (5x), phosphonate (5y), sulfonate (5z), and perfluorinated alkyls (5aa, 5ab and 5ac)) were successfully applied. The scope of EBX partners was also broad, including alkyl chains (5s, 5t, 5u and 5z), alkenyl (5w) and aromatic substituents (5y and 5aa) that contained several functional groups like halide (5s and 5y) or a silyl ether (5z) and carbocycles, such as a cyclopropane (5u). In addition, further


Scheme 3. Substrate scope with simultaneous variation of the three components. Unless otherwise noted, the reaction conditions are as follows: **2a-h** (0.3 mmol), **3a-k** solution in 1.0 mL DCM (0.6 mmol), **4s-4ac** (1.2 mmol), DCM (2.0 mL). All yields refer to the isolated products. ^[a]Reaction conducted at 40 °C.

Next, we used disubstituted diazo compounds (Scheme 4A). Diazo compounds bearing a methyl or a phenyl substituent furnished **5ad** and **5ae** in 43% and 57% yield respectively, without the need to reoptimize the reaction conditions. A cyclic diazo compound provided **5af** in moderate yield. Finally, we investigated a substrate having a pendant hydroxy group for intramolecular nucleophile attack. The desired tetrahydropyran **5ag** was formed, albeit in low yield.

The high efficiency of the three-component reaction with trifluoromethyl-substituted diazo compounds is especially interesting, as organofluorine compounds are of significant importance in the pharmaceutical, agrochemical and materials industry.^[19] For example, Efavirenz (**10**), which contains a CF₃-propargyl motif, is one of the most frequently prescribed antiretroviral drug used in HIV treatment. We decided to apply our methodology to access the Lonza intermediate **5ah**, a direct precursor to Efavirenz (**10**) (Scheme 4B).^[20] We envisaged the use of *tert*-butyl carbamate as nucleophile, anticipating that O-attack followed by loss of the *tert*-butyl group could generate the desired NH₂-carbamate. In this case, the number of equivalents of reagents, as well as the catalyst loading, could be reduced as

COMMUNICATION


there was no competitive O-H insertion pathway. The desired molecule **5ah** was obtained in good yield without the formation of products from N-H insertion.^[21] Our methodology also gave access to structurally diverse analogues. The poly-trifluoromethylated compound **5ai**, bearing a thiophene on the alkyne, was synthesized in good yield, as well as ether **5aj** bearing a nitrile group.^[22] Finally, the carbamate derivative **5ak** containing a protected amine and an aryl bromide was obtained in 31% yield.



Scheme 4. Substrate scope with disubstituted diazo compounds and Efavirenz analogues. Unless otherwise noted, the reaction conditions are as follows: **2a-k** (0.3 mmol), **3I-s** solution in 1.0 mL DCM (0.6 mmol), **4a-4af** (1.2 mmol), DCM (2.0 mL). All yields refer to the isolated products. ^[a]The reaction was conducted at RT. ^[b]No alcohol was used. ^[c]BocNH₂ **4ad** (1.3 equiv), **3p-s** (1.3 equiv) and Cu(CH₃CN)₄PF₆ (5 mol%) were used. ^[c]Yield determined by ¹⁹F NMR spectroscopy.

To gain insights into the mechanism, several control experiments were carried out (Scheme 5A). First, when ethyl diazoacetate (3a) was reacted with ethanol (4a) in presence of 10 mol% of Cu(CH₃CN)₄PF₆, we observed the formation of **6a** by ¹H NMR spectroscopy analysis of the reaction mixture (Eq. (1)). However, no three-component product 5a was observed after the subsequent addition of TIPS-EBX (2a) to this solution. This indicates that 6a is not an intermediate in the catalytic cycle. When mixing reagent 2a and diazo 3a in the presence of the copper catalyst, rapid evolution of nitrogen occurred and we mainly observed the formation of diethyl fumarate/maleate (11) (Eq. (2)).^[3d] Other products resulting from a minor decomposition (ca. 10%) of the hypervalent iodine reagent 2a could not be identified. A ¹H NMR titration experiment was then carried out using Cu(CH₃CN)₄PF₆ in combination with EBX 2a. Progressive shifts of the aromatic ¹H were observed upon addition of the copper salt, with a significant diminution after one equivalent (See Figure S3 in Supporting Information). A ¹³C NMR spectrum of an equimolar mixture of Cu(CH₃CN)₄PF₆ and **2a** in CD₂Cl₂ showed major changes in the ¹³C-alkyne signals, while other peaks remained nearly constant (See Figure S5 in Supporting Information). When ethanol (4 equiv.) and Cu(CH₃CN)₄PF₆ (1

equiv.) were mixed together in CD₂Cl₂, no ligand exchange was observed (See Figure S6 in Supporting Information). These NMR studies indicated an interaction between the Cu catalyst and the EBX reagent 2a, probably through the alkyne, but no complete reaction, making oxidative addition of the reagent onto copper to form a Cu(III) intermediate a less probable pathway.^[23] We then attempted the trapping of a potential Cu-carbene intermediate through a cyclopropanation reaction using one equivalent of ethyl diazoacetate (3a) and 4 equivalents of ethanol (4a) and styrene (Eq. (3)). Cylcopropane 12 was obtained in 21% NMR yield, and the three-component product 5a was formed in 62% yield. Aside from supporting the existence of a metal carbene, this competitive experiment, also shows that attack of ethanol to form a putative oxonium ylide is faster than cyclopropanation. Finally, we reexamined the reaction of 2a, 3a and benzyl alcohol (4b) in presence of chiral ligand 9 under the optimized reaction conditions. The product 5a was obtained in poor yield as a racemic compound (Eq. (4)). This may indicate that ligand decomplexation is required for the reaction to proceed, making the development of an enantioselective method highly challenging.



Scheme 5. Mechanistic studies and proposed catalytic cycle. ^[a]Yields determined by ¹H NMR analysis of the crude reaction mixture.

Based on the results of our control experiments and the relevant literature on metal-ylide based multicomponent reactions,^[3] our proposed catalytic cycle is presented in Scheme 5B. Starting with Cu(I) catalyst I, reaction with diazo compound **3** and the hypervalent iodine reagents generates electrophilic copper-carbene II with alkyne-bound EBX. At this stage, it is difficult to establish if coordination of the hypervalent iodine

COMMUNICATION

reagents is occurring before or after carbene formation. From II, two pathways are possible: With carboxylate reagent 1, intramolecular oxygen attack directly followed by alkynylation leads to two-component product 7; With bis-trifluoromethyl reagents 2, the oxygen atom of the benziodoxole is not nucleophilic enough, and attack of the external alcohol 4 forms oxonium-ylide intermediate III. Intramolecular alkynylation by EBX reagent 2 with simultaneous deprotonation then generates the 3component product 5 and iodide 13, releasing the copper catalyst. Undesired 1,2-H shift on the transient ylide III produces the O-H insertion product 6. Further studies will be needed to establish the mechanism of the alkynylation step.

In conclusion, we have reported a general copper-catalyzed three-component reactions of alcohols, diazo compounds and alkynyl benziodoxole reagents. The reaction can be done under mild conditions and each of the three partners can be extensively varied, leading to maximal structural diversity. Preliminary mechanism investigations support a mechanism involving subsequent formation of copper carbene and ylide intermediates, followed by electrophilic alkynylation. Future work in our laboratory will focus on a more in-depth understanding of the reaction mechanism, the development of an enantioselective variation and the use of other classes of nucleophilic partners in the three-component transformation.

Acknowledgements

We thank the Swiss National Science Foundation (Grant No. 200021_165788) and EPFL for financial support. We thank Dr R. Scopelliti and Dr F. F. Tirani from ISIC at EPFL for X-ray analysis.

Keywords: multi-component reactions (MCR); copper catalysis; molecular complexity; hypervalent iodine reagents; carbenes.

- Multicomponent Reactions, Ed. J. Zhu, H. Bienaymé, Wiley-VCH Verlag, 2005.
- a) A. Domling, I. Ugi, Angew. Chem., Int. Ed. 2000, 39, 3168; b) B. B.
 Toure, D. G. Hall, Chem. Rev. 2009, 109, 4439; c) E. Ruijter, R.
 Scheffelaar, R. V. A. Orru, Angew. Chem., Int. Ed. 2011, 50, 6234; d) A.
 Domling, W. Wang, K. Wang, Chem. Rev. 2012, 112, 3083; e) Q. Wang,
 D. X. Wang, M. X. Wang, J. P. Zhu, Acc. Chem. Res. 2018, 51, 1290.
- a) X. Guo, W. Hu, Acc. Chem. Res. 2013, 46, 2427; b) D. F. Chen, Z. Y.
 Han, X. L. Zhou, L. Z. Gong, Acc. Chem. Res. 2014, 47, 2365; c) D.
 Zhang, W. H. Hu, Chem. Rec. 2017, 17, 739; For a general review on the use of diazo compounds, see: A. Ford, H. Miel, A. Ring, C. N. Slattery, A. R. Maguire, M. A. McKervey, Chem. Rev. 2015, 115, 9981.
- Selected examples: a) H. Huang, X. Guo, W. Hu, Angew. Chem., Int. Ed. [4] 2007, 46, 1337; b) X. Y. Guan, L. P. Yang, W. H. Hu, Angew. Chem., Int. Ed. 2010, 49, 2190; c) H. Qiu, M. Li, L. Q. Jiang, F. P. Lv, L. Zan, C. W. Zhai, M. P. Doyle, W. H. Hu, Nat. Chem. 2012, 4, 733; d) S. Jia, D. Xing, D. Zhang, W. Hu, Angew. Chem., Int. Ed. 2014, 53, 13098; e) X. C. Ma, J. Jiang, S. Y. Lv, W. F. Yao, Y. Yang, S. Y. Liu, F. Xia, W. H. Hu, Angew. Chem., Int. Ed. 2014, 53, 13136; f) X. Lv, Z. Kang, D. Xing, W. Hu, Org. Lett. 2018, 20, 4843; g) J. Che, A. Gopi Krishna Reddy, L. Niu, D. Xing, W. Hu, Org. Lett. 2019, 21, 4571; h) S. Yu, R. Hua, X. Fu, G. Liu, D. Zhang, S. Jia, H. Qiu, W. Hu, Org. Lett. 2019, 21, 5737; i) W. Hu, X. Xu, J. Zhou, W.-J. Liu, H. Huang, J. Hu, L. Yang, L.-Z. Gong, J. Am. Chem. Soc. 2008, 130, 7782; j) D. F. Chen, F. Zhao, Y. Hu, L. Z. Gong, Angew. Chem., Int. Ed. 2014, 53, 10763; k) Y. Xia, S. Feng, Z. Liu, Y. Zhang, J. Wang, Angew. Chem., Int. Ed. 2015, 54, 7891; I) C. Wang, F. Ye, C. Wu, Y. Zhang, J. Wang, J. Org. Chem 2015, 80, 8748; m) C. G. Wu, Z. X. Liu, Z. K. Zhang, F. Ye, G. S. Deng, Y. Zhang, J. B. Wang, Adv. Synth. Catal. 2016, 358, 2480; n) S. K. Alamsetti, M. Spanka, C. Schneider, Angew. Chem., Int. Ed. 2016, 55, 2392; o) S. Goudedranche, C. Besnard, L. Egger, J. Lacour, Angew. Chem., Int. Ed. 2016, 55, 13775; p) W. Yuan, K. J. Szabó, ACS Catalysis 2016, 6, 6687; q) M. Lübcke, W. Yuan, K. J.


Szabó, Org. Lett. 2017, 19, 4548; r) M. Lübcke, D. Bezhan, K. J. Szabó, Chemical Science 2019, 10, 5990; s) X.-S. Liang, R.-D. Li, X.-C. Wang, Angew. Chem., Int. Ed. 2019, 58, 13885; t) J. Yu, L. Chen, J. Sun, Org. Lett. 2019, 21, 1664.

- [5] A. Yoshimura, V. V. Zhdankin, Chem. Rev 2016, 116, 3328-3435.
- a) J. Kaschel, D. B. Werz, Angew. Chem., Int. Ed. 2015, 54, 8876; b) Y.
 Li, D. P. Hari, M. V. Vita, J. Waser, Angew. Chem., Int. Ed. 2016, 55, 4436; c) D. P. Hari, P. Caramenti, J. Waser, Acc. Chem. Res. 2018, 51, 3212.
- a) J. Tao, R. Tran, G. K. Murphy, J. Am. Chem. Soc. 2013, 135, 16312;
 b) G. K. Murphy, F. Z. Abbas, A. V. Poulton, Adv. Synth. Catal. 2014, 356, 2919;
 c) G. S. Sinclair, R. Tran, J. Tao, W. S. Hopkins, G. K. Murphy, Eur. J. Org. Chem. 2016, 4603;
 d) Z. Zhao, K. G. Kulkarni, G. K. Murphy, Adv. Synth. Catal. 2017, 359, 2222.
- [8] N. Döben, H. Yan, M. Kischkewitz, J. Mao, A. Studer, Org. Lett. 2018, 20, 7933.
- [9] D. Zhu, Y. Yao, R. Zhao, Y. Liu, L. Shi, Chem. Eur. J. 2018, 24, 4805.
- a) D. P. Hari, J. Waser, *J. Am. Chem. Soc.* 2016, *138*, 2190; b) D. P. Hari, J. Waser, *J. Am. Chem. Soc.* 2017, *139*, 8420; c) D. P. Hari, L. Schouwey, V. Barber, R. Scopelliti, F. Fadaei-Tirani, J. Waser, *Chem. Eur. J.* 2019, *25*, 9522.
- [11] a) W. Yuan, L. Eriksson, K. J. Szabó, Angew. Chem., Int. Ed. 2016, 55, 8410; b) B. K. Mai, K. J. Szabó, F. Himo, ACS Catal. 2018, 8, 4483.
- [12] For selected examples of propargylic ether synthesis, see: a) E. B. Bauer, *Synthesis* 2012, 44, 1131; b) Y. X. Zhu, L. Sun, P. Lu, Y. G. Wang, ACS *Catal.* 2014, 4, 1911; c) M. Baxter, Y. Bolshan, *Chem. Eur. J.* 2015, 21, 13535; e) K. Nakajima, M. Shibata, Y. Nishibayashi, *J. Am. Chem. Soc.* 2015, 137, 2472.
- [13] a) V. V. Zhdankin, C. J. Kuehl, A. P. Krasutsky, J. T. Bolz, A. J. Simonsen, J. Org. Chem. 1996, 61, 6547; b) Y. Li, J. P. Brand, J. Waser, Angew. Chem., Int. Ed. 2013, 52, 6743; c) Y. Li, J. Waser, Angew. Chem., Int. Ed. 2015, 54, 5438; d) J. Wu, N. Yoshikai, Angew. Chem., Int. Ed. 2015, 54, 11107.
- [14] No product **5a** was obtained when using CuI, CuCN, Cu(II)trifluoroacetylycetonate or Cu(OAc)₂ as catalyst.
- [15] On scope scale, better results were obtained when diazo compound 3 was added slowly as a solution in CH₂Cl₂ (0.6 M, addition rate 1 mL/h).
- [16] H. C. Beyerman, G. J. Heiszwolf, *Recl. Trav. Chim. Pays-Bas* 1965, 84, 203.
- [17] R. G. Salomon, J. K. Kochi, J. Am. Chem. Soc. 1973, 95, 3300.
- [18] H. Zhang, G. Wu, H. Yi, T. Sun, B. Wang, Y. Zhang, G. Dong, J. Wang, Angew. Chem. Int. Ed. 2017, 56, 3945.
- [19] Organofluorine Compounds in Biology and Medicine, V. P. Reddy, Elsevier, 2015.
- [20] D. Dai, X. Long, A. Kulesza, J. Reichwagen, B. Luo and Y. Guo (Lonza Ltd), PCT Int. Appl. WO2012097510, 2012.
- [21] E. C. Lee, G. C. Fu, *J. Am. Chem. Soc.* **2007**, *129*, 12066.
- [22] The structure of 5aj was confirmed by X-ray analysis. The structure is available at the Cambridge Crystallographic Data Center (ccdc number: 1985456).
- [23] The formation of Cu(III) intermediates by reaction oxidation with hypervalent iodine reagents has been proposed, see for example: a) D. Holt, M. J. Gaunt, Angew. Chem., Int. Ed. 2015, 54, 7857; b) M. G. Suero, E. D.Bayle, B. S. L. Collins, M. J. Gaunt, J. Am. Chem. Soc. 2013, 135, 5332; c) A. J. Hickman, M. S. Sanford, Nature 2012, 484, 177.

WILEY-VCH

COMMUNICATION

COMMUNICATION



Power 3: A copper-catalyzed three-component reaction of hypervalent iodine reagents, diazo compounds and alcohols has been developed. The transformation gives access to functionalized propargylic ethers with high structural diversity, as variation of the three partners with numerous functional groups was tolerated. The reaction is speculated to proceed via a copper oxonium ylide intermediate.

Guillaume Pisella, Alec Gagnebin and Jerome Waser*

Page No. – Page No.

Three-Component Reaction for the Synthesis of Highly Functionalized Propargyl Ethers

Supporting Information

(110 pages)

Authors contributions: G. P. performed and planned the experiments and prepared the manuscript and the experimentals part, A. G. performed the experiments as a laboratory technician in formation under the supervision of G. P., J. W. supervised the project, prepared the manuscript and corrected the experimental part.

Table of Contents

| 1. | General Methods | 2 |
|----|--|------|
| 2. | Optimization of the reaction conditions | 3 |
| 3. | 3-component reaction of alcohols, diazo compounds and EBX reagents | 7 |
| 4. | Control experiments and mechanistic studies | . 24 |
| 5. | Synthesis of diazo-compounds | . 31 |
| 6. | Preparation of EBX reagents | . 42 |
| 7. | Spectra of new compounds | . 49 |
| 8. | X-ray diffraction parameters and data for 5aj | 110 |

1. General Methods


All reactions were carried out in oven dried glassware under an atmosphere of nitrogen, unless stated otherwise. For quantitative flash chromatography technical grade solvents were used. For flash chromatography for analysis, HPLC grade solvents from Sigma-Aldrich were used. THF, Et₂O, CH₃CN, toluene, hexane and CH₂Cl₂ were dried by passage over activated alumina under nitrogen atmosphere (H_2O content < 10 ppm, Karl-Fischer titration). The solvents were degassed by Freeze-Pump-Thaw method when mentioned. All chemicals were purchased from Acros, Aldrich, Fluka, Fluorochem, TCI, VWR or Merck and used as such unless stated otherwise. Chromatographic purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. TLC was performed on Merck silica gel 60 F254 TLC aluminium plates and visualized with UV light, permanganate stain or 4-anisaldehyde stain. Melting points were measured on a Büchi B-540 melting point apparatus using open glass capillaries, the data is uncorrected. ¹H NMR spectra were recorded on a Brucker DPX-400 400 MHz spectrometer in CDCl₃, DMSO- d_6 , CD₂Cl₂ or CD₃OD, all signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal DMSO signal at 2.50 ppm, the internal dichloromethane signal at 5.32 ppm or the internal methanol signal at 3.30 ppm as standard. The data is being reported as (s = singlet, d = doublet, t = triplet, q = quadruplet, qi = quintet, m = multiplet or unresolved, br = broad signal, app = apparent, coupling constant(s) in Hz, integration, interpretation). ¹³C NMR spectra were recorded with ¹Hdecoupling on a Brucker DPX-400 100 MHz spectrometer in CDCl₃, DMSO-d₆, CD₂Cl₂, or CD₃OD, all signals are reported in ppm with the internal chloroform signal at 77.0 ppm, the internal DMSO signal at 39.5 ppm, the internal dichloromethane signal at 54.0 ppm or the internal methanol signal at 49.0 ppm as standard. Infrared spectra were recorded on a JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are reported as cm^{-1} (w = weak, m = medium, s = strong, br = broad). High resolution mass spectrometric measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API. HPLC measurements were done on a Agilent 1260 Infinity autosampler using a CHIRALPAK IA column from DAICEL Chemical.

2. Optimization of the reaction conditions

a) Screening of the electrophilic alkynyl source, catalyst loading and ligands


In a N₂-filled glovebox, a catalytic solution was prepared by mixing $Cu(CH_3CN)_4BF_4$ (x mol%) and ligand (8 - 9) (y mol%) (when applicable) in CD_2CI_2 (2.00 mL) at room temperature for 1 h. The catalytic solution was prepared in EtOH when used as solvent.


0.40 mL of the catalytic solution was then added to a stirring solution of hypervalent iodine reagent (1, **2a** or **14**) (0.08 mmol, 1.00 equiv.), EtOH (**4a**) (w equiv.) and ethyl diazoacetate (**3a**) (v equiv.) in CD_2Cl_2 (0.40 mL). The resulting reaction mixture was stirred at room temperature for 1 h. After this time, a ¹H NMR spectrum of the reaction mixture was recorded. Yields were obtained by comparing the integration of the signals at 8.43-8.36 ppm for **2a**, 8.17 ppm for the corresponding alcohol, 4.72 ppm for **5a** and 4.03 ppm for **6a**, and are not calibrated.




| entry | EBX (1 equiv.) | EDA 3a (v equiv.) | EtOH 4a (w equiv.) | Cu cat. (x mol%) | ligand (y mol%) | yield 5a/6a/7a [%] ^a |
|-------|-------------------|-----------------------------|-----------------------|--|----------------------|------------------------------------|
| 1 | 1 | 2.00 | as solvent | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | 8 (4 mol%) | 50/n.d./32 |
| 2 | 1 | 2.00 | as solvent | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | 9 (4 mol%) | 63/n.d./30 |
| 3 | 1 | 2.00 | 10.0 | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | 9 (4 mol%) | 22/n.d./52 |
| 4 | 2a | 2.00 | as solvent | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | 9 (4 mol%) | 62/n.d./- |
| 5 | 14 | 2.00 | as solvent | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | 9 (4 mol%) | -/n.d./- |
| 6 | 2a | 2.00 | as solvent | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | - | 100/48/- |
| 7 | 2a | 2.00 | 10.0 | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | - | 100/47/- |
| 8 | 2a | 2.00 | 4.00 | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | - | 80/49/- |
| 9 | 2a | 2.00 | 2.00 | Cu(CH ₃ CN) ₄ BF ₄ (4 mol%) | - | 53/51/- |
| 10 | 2a | 2.00 | 2.00 | Cu(CH ₃ CN) ₄ BF ₄ (10 mol%) | - | 62/38/- |
| 11 | 2a | 1.00 | 2.00 | Cu(CH ₃ CN) ₄ BF ₄ (10 mol%) | - | 34/42/- |

[a] Determined by ¹H NMR analysis








It was found that reagent **2a** was converted only to the desired three-component product **5a**. The absence of a ligand was beneficial for the formation of **5a**. Increasing the Cu catalyst loading to 10 mol% improved the formation of **5a**.

b) Screening of additives

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄BF₄ (2.52 mg, 8.00 μ mol, 0.10 equiv.), TIPS-EBX **2a** (44.0 mg, 80.0 μ mol, 1.00 equiv.) and the additive (x equiv.), if solid. The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by EtOH (**4a**) (9.34 μ L, 160 μ mol, 2.00 equiv.), the additive (x equiv.), if liquid, and ethyl diazoacetate (**3a**) (19.0 μ L, 160 μ mol, 2.00 equiv., 87%wt in DCM). The resulting reaction mixture was stirred at room temperature for 1 h. After this time, ¹H NMR spectrum of the reaction mixture was recorded.



None of the additives screened above were found to improve the formation of the three-component product **5a**.

c) Screening of the copper catalysts

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu cat. (8.00 μ mol, 0.10 equiv.) and TIPS-EBX **2a** (44.0 mg, 80.0 μ mol, 1.00 equiv.). The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by EtOH (**4a**) (9.30 μ L, 160 μ mol, 2.00 equiv.) and ethyl diazoacetate (**3a**) (19.0 μ L, 160 μ mol, 2.00 equiv., 87%wt in DCM). The resulting reaction mixture

was stirred at room temperature for 1 h. After this time, ¹H NMR spectrum of the reaction mixture was recorded.


| $F_{3}C$ F | N ₂ CO ₂ Et + EtC 3a 4a (2 equiv.) (2 equiv.) | CD ₂ Cl ₂ (0.1 M) RT, 1 h | TIPS EtO H CO ₂ Et 5a | + $H CO_2Et$ 6a |
|--|---|---|---|--------------------|
| | entry | Cu cat. | yield 5a/6a [%] ^a | |
| | 1 | Cu(CH ₃ CN) ₄ PF ₆ | 74/18 | |
| | 2 | CuOTf•toluene | 60/33 | |
| | 3 | Cu(OTf) ₂ | 47/11 | |
| | 4 | CuCl ₂ | 30/17 | |
| | 5 | CuBr | 16/24 | |
| | 6 | Cul | no reaction | |
| | 7 | CuTC | 10/40 | |
| | 8 | CuCN | no reaction | |
| | 9 | CuOAc | no reaction | |
| | 10 | $Cu(C_5H_4F_3O_2)_2$ | no reaction | |
| | 11 | Cu(OAc) ₂ | no reaction | |

[a] Determined by ¹H NMR analysis

It was found that $Cu(CH_3CN)_4PF_6$ was superior to $Cu(CH_3CN)_4BF_4$ to catalyze the formation of the three-component product **5a**.

d) Fine-tuning of the last parameters

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₄CN)₄PF₆ (2.52 mg, 8.00 μ mol, 0.10 equiv.) and TIPS-EBX **2a** (44.0 mg, 80.0 μ mol, 1.00 equiv.). The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by EtOH (**4a**) (w equiv.) and ethyl diazoacetate (**3a**) (v equiv.). The resulting reaction mixture was stirred at room temperature for 1 h. After this time, ¹H NMR spectrum of the reaction mixture was recorded.



[a] Determined by ¹H NMR analysis [b] Isolated yield [c] The diazo compounds was added as a 0.6 M solution in DCM in 1 h *via* seringe pump. Reaction perfomed on scope scale (2a, 0.3 mmol)

It was found that 4 equivalents of EtOH **4a** was beneficial for the formation of the three-component product **5a**. It was found that the slow addition of a diluted solution of EDA **3a** improved the yield of **5a**.


3. 3-component reaction of alcohols, diazo compounds and EBX reagents

 $R^{1}OH + R^{2}R^{3} + R^{4} - CF_{3} - DCM, RT, 2 h$ 4a - 4'f 3a - 3s 2a - 2k 5a - 5ak

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (11.2 mg, 30.0 μ mol, 0.10 equiv.), EBX reagent (**2a** – **2k**) (0.30 mmol, 1.00 equiv.) and alcohol (**4a** – **4af**) (1.20 mmol, 4.00 equiv.), if solid. The vial was capped, removed from the glovebox and dry DCM (2.0 mL) was added. The alcohol was added at this point if liquid. To the resulting solution was added a 0.6 M solution of diazo compound (**3a** – **3s**) (0.60 mmol, 2.00 equiv.) in dry DCM in 1 h *via* seringe pump at 25 °C. The system was mainted isobaric with a filled balloon with N₂. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography using EtOAc/pentane as eluent (the solvent ratio indicated in the Rf measurement was used), directly without further work-up to afford the corresponding product (**5a** – **5ak**).


General procedure B: Three-component reaction at 40 °C.

General procedure A: Three-component reaction at 25 °C.



In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (11.2 mg, 30.0 μ mol, 0.10 equiv.), EBX reagent (**2a** – **2k**) (0.30 mmol, 1.00 equiv.) and alcohol (**4a** – **4af**) (1.20 mmol, 4.00 equiv.), if solid. The vial was capped, removed from the glovebox and dry DCM (2.0 mL) was added. The alcohol was added at this point if liquid. To the resulting solution was added a 0.6 M solution of diazo compound (**3a** – **3s**) (0.60 mmol, 2.00 equiv.) in dry DCM in 1 h *via* seringe pump at 40 °C. The system was mainted isobaric with a filled balloon with N₂. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography using EtOAc/pentane as eluent (the solvent ratio indicated in the R_f measurement was used), directly without further work-up to afford the corresponding product (**5a** – **5ak**).


Ethyl 2-ethoxy-4-(triisopropylsilyl)but-3-ynoate (5a)



Following general procedure A, starting from ethanol (**4a**) (70.0 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**6a**) as a colorless oil (87 mg, 0.28 mmol, 93%). R_f = 0.29 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.75 (s, 1H, *H*CC=C), 4.35 – 4.17 (m, 2H, CH₂OC(O)), 3.79 (dq, *J* = 9.1, 7.0 Hz, 1H, OCH₂CH₃), 3.65 (dq, *J* = 9.2, 7.0 Hz, 1H, OCH₂CH₃), 1.29 (m, 6H, 2 x OCH₂CH₃), 1.13 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 100.4, 89.2, 69.2, 64.6, 62.0, 18.7, 15.2, 14.2, 11.2; IR (v_{max},


cm⁻¹) 2943 (m), 2867 (m), 2175 (w), 1759 (s), 1464 (m), 1281 (m), 1192 (m), 1116 (s), 1032 (s), 882 (s), 677 (s), 661 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₇H₃₂NaO₃Si⁺ 335.2013; Found 335.2009.

Ethyl 2-(benzyloxy)-4-(triisopropylsilyl)but-3-ynoate (5b)




Following general procedure A, starting from benzyl alcohol (**4b**) (124 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5b**) as a colorless oil (85 mg, 0.23 mmol, 76%). R_f = 0.33 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.27 (m, 5H, ArH), 4.86 – 4.79 (m, 1H, OCH₂Ph), 4.79 – 4.69 (m, 2H, OCH₂Ph and HCC=C), 4.35 – 4.16 (m, 2H, OCH₂CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.13 – 0.97 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.6, 136.9, 128.7, 128.6, 128.2, 100.0, 90.0, 70.4, 68.1, 62.0, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (m), 2866 (m), 2175 (w), 1756 (s), 1463 (m), 1275 (m), 1192 (s), 1111 (s), 1031 (s), 882 (s), 739 (m), 697 (s), 677 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₂H₃₄NaO₃Si⁺ 397.2169; Found 397.2172.

Ethyl 2-((4-bromobenzyl)oxy)-4-(triisopropylsilyl)but-3-ynoate (5c)



Following general procedure A, starting from 4-bromobenzyl alcohol (**4c**) (224 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5c**) as a colorless oil (99 mg, 0.22 mmol, 73%). R_f = 0.29 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.45 (m, 2H, Ar*H*), 7.32 – 7.24 (m, 2H, Ar*H*), 4.80 – 4.72 (m, 2H, OCH₂Ar and *H*CC≡C), 4.68 (m, 1H, OCH₂Ar), 4.35 – 4.16 (m, 2H, OCH₂CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.12 – 0.96 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.5, 136.1, 131.7, 130.2, 122.2, 99.7, 90.4, 69.6, 68.2, 62.1, 18.7, 14.2, 11.2; IR (v_{max}, cm⁻¹) 2943 (m), 2892 (m), 2866 (m), 1755 (s), 1489 (m), 1463 (m), 1367 (m), 1279 (m), 1194 (s), 1112 (s), 1070 (s), 1039 (s), 1012 (s), 882 (s), 801 (s), 677 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₂H₃₃BrNaO₃Si⁺ 475.1275; Found 475.1279.


Ethyl 2-(furan-2-ylmethoxy)-4-(triisopropylsilyl)but-3-ynoate (5d)



Following general procedure A, starting from furfuryl alcohol (**4d**) (104 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5d**) as a colorless oil (69 mg, 0.19 mmol, 63%). R_f = 0.28 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 1.9, 0.8 Hz, 1H, Ar*H*), 6.39 (dd, *J* = 3.2, 0.8 Hz, 1H, Ar*H*), 6.34 (dd, *J* = 3.2, 1.9 Hz, 1H, Ar*H*), 4.81 – 4.67 (m, 3H, *H*CC≡C and *CH*₂Ar), 4.33 – 4.16 (m, 2H, OCH₂CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.12 – 0.96 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.4, 150.5, 143.4, 110.8, 110.5, 99.6, 90.4, 67.8, 62.1, 61.9, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (s), 2866 (s), 2174 (w),


1756 (s), 1464 (m), 1277 (m), 1193 (s), 1151 (s), 1097 (s), 1043 (s), 1015 (s), 921 (m), 883 (s), 737 (s), 676 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₀H₃₂NaO₄Si⁺ 387.1962; Found 387.1974.

Ethyl 2-(cyclohexyloxy)-4-(triisopropylsilyl)but-3-ynoate (5e)




Following general procedure A, starting from cyclohexanol (**4e**) (127 µL, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5e**) as a colorless oil (99 mg, 0.27 mmol, 90%). R_f = 0.33 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 1H, HCC=C), 4.36 – 4.15 (m, 2H, OCH₂CH₃), 3.65 (tt, *J* = 9.6, 3.9 Hz, 1H, O-CH-_{cyclohexyl}), 2.04 – 1.90 (m, 2H, 2 x CH-_{cyclohexyl}), 1.82 – 1.69 (m, 2H, 2 x CH-_{cyclohexyl}), 1.56 – 1.12 (m, 9H, 2 x CH₂-_{cyclohexyl} and OCH₂CH₃), 1.11 – 0.93 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 168.2, 101.3, 88.6, 77.1, 67.2, 61.9, 32.9, 31.9, 25.8, 24.5, 24.3, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (m), 2866 (m), 2175 (w), 1756 (s), 1463 (m), 1275 (m), 1192 (s), 1111 (s), 1040 (s), 882 (s), 739 (m), 697 (s), 676 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₁H₃₈NaO₃Si⁺ 389.2482; Found 389.2487.

Ethyl 2-((1,3-difluoropropan-2-yl)oxy)-4-(triisopropylsilyl)but-3-ynoate (5f)



Following general procedure A, starting from 1,2-difluoro-2-propanol (**4f**) (93.0 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5f**) as a colorless oil (68 mg, 0.19 mmol, 63%). R_f = 0.27 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.99 (s, 1H, HCC=C), 4.78 – 4.64 (m, 2H, 2 x CH₂F), 4.64 – 4.52 (m, 2H, 2 x CH₂F), 4.36 – 4.17 (m, 3H, OCH and OCH₂CH₃), 1.30 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.12 – 0.95 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.4, 99.4, 90.9, 81.5 (ddd, *J* = 171.5, 15.9, 6.5 Hz), 74.6 (t, *J* = 20.6 Hz), 69.2, 62.2, 18.6, 14.2, 11.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2; IR (v_{max}, cm⁻¹) 2945 (m), 2894 (m), 2867 (m), 2176 (w), 1755 (s), 1464 (m), 1282 (m), 1200 (s), 1121 (s), 1091 (s), 1028 (s), 970 (m), 882 (s), 677 (s), 660 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₈H₃₂F₂NaO₃Si⁺ 385.1981; Found 385.1987.


Ethyl 2-(tert-butoxy)-4-(triisopropylsilyl)but-3-ynoate (5g)



Following general procedure A, starting from *tert*-butanol (**4g**) (115 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5g**) as a colorless oil (70 mg, 0.21 mmol, 69%). R_f = 0.40 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.76 (s, 1H, HCC=C), 4.34 – 4.15 (m, 2H, OCH₂CH₃), 1.31 – 1.26 (m, 12H, tBu


and OCH₂CH₃), 1.10 - 0.93 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 168.8, 103.6, 87.3, 76.5, 63.2, 61.9, 28.1, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2961 (m), 2943 (m), 2866 (m), 2177 (w), 1766 (s), 1741 (m), 1464 (m), 1367 (s), 1275 (m), 1254 (m), 1188 (s), 1096 (s), 1033 (s), 882 (s), 750 (m), 677 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₉H₃₆NaO₃Si⁺ 363.2326; Found 363.2329.

Ethyl 2-(allyloxy)-4-(triisopropylsilyl)but-3-ynoate (5h)




Following general procedure B, starting from allyl alcohol (**4h**) (115 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5h**) as a colorless oil (45 mg, 0.14 mmol, 46%). R_f = 0.31 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 5.94 (dddd, *J* = 17.0, 10.3, 6.5, 5.4 Hz, 1H, CH=CH₂), 5.34 (dq, *J* = 17.2, 1.6 Hz, 1H, CH=CH₂), 5.25 (dq, *J* = 10.4, 1.2 Hz, 1H, CH=CH₂), 4.79 (s, 1H, HCC=C), 4.36 – 4.12 (m, 4H, OCH₂CH and OCH₂CH₃), 1.30 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.12 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.6, 133.6, 118.9, 100.1, 89.7, 69.7, 68.2, 62.0, 18.7, 14.2, 11.2; IR (v_{max}, cm⁻¹) 2943 (m), 2866 (s), 2175 (w), 1758 (s), 1464 (m), 1270 (m), 1189 (s), 1111 (s), 1038 (s), 996 (s), 921 (m), 882 (s), 676 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₈H₃₂NaO₃Si⁺ 347.2013; Found 347.2008.

Ethyl 2-((2-methyl-4-phenylbut-3-yn-2-yl)oxy)-4-(triisopropylsilyl)but-3-ynoate (5i)




Following general procedure B, starting from 4-phenyl-2-methyl-3-butyn-2-ol (**4i**) (192 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5i**) as a colorless oil (54 mg, 0.13 mmol, 42%). R_f = 0.38 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.38 (m, 2H, Ar*H*), 7.33 – 7.27 (m, 3H, Ar*H*), 5.20 (s, 1H, *H*CC=C), 4.35 – 4.12 (m, 2H, OCH₂CH₃), 1.68 (s, 3H, C(CH₃)₂), 1.62 (s, 3H, C(CH₃)₂), 1.26 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.09 – 0.93 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 131.9, 128.6, 128.4, 122.5, 102.8, 90.1, 88.0, 85.8, 73.7, 65.4, 61.9, 30.0, 29.4, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (m), 2866 (m), 2178 (w), 1765 (s), 1741 (m), 1464 (m), 1283 (m), 1269 (m), 1184 (s), 1152 (s), 1091 (s), 1038 (s), 882 (s), 756 (s), 690 (s), 677 (s), 661 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₆H₃₈NaO₃Si⁺ 449.2482; Found 449.2485.

Ethyl 2-hydroxy-4-(triisopropylsilyl)but-3-ynoate (5j)




Adapted from general procedure A, starting from water (**4j**) (54 μ L, 3.0 mmol, 10.0 equiv.), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol, 1.00 equiv.), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM, 2.00 equiv.), afforded the title compound (**5j**) as a colorless oil (28 mg, 0.10 mmol, 33%). R_f = 0.11 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.85 (d, *J* = 5.2 Hz, 1H, HCC=C), 4.41 – 4.20 (m, 2H, OCH₂CH₃), 3.00 (br d, *J* = 7.0 Hz, 1H, OH), 1.32 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.09 – 1.02 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 170.6, 102.3, 87.4, 62.8, 62.1, 18.6, 14.2, 11.2; IR (v_{max}, cm⁻¹) 3469 (br w), 2943 (s), 2866 (s), 2177 (w), 2099 (m), 1745 (s), 1465 (m), 1301 (m), 1259 (m), 1202 (m), 1093 (s), 1028 (s), 882 (s), 677 (s), 661 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₅H₂₈NaO₃Si⁺ 307.1700; Found 307.1700.

Ethyl 2-(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)-4-(triisopropylsilyl)but-3-ynoate (5k)




Following general procedure A, starting from (-)-menthol (4k) (188 mg, 1.20 mmol), ((3,3bis(trifluoromethyl)- $1\lambda^3$ -benzo[d][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (2a) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (3a) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (5k) (50:50 dr in the crude ¹H NMR) as a colorless oil (107 mg, 0.25 mmol, 84%). A pure analytical sample of each diastereoisomer was isolated by PTLC using EtOAc/pentane 4:96 as eluent. Diaster 5k: R_f = 0.35 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 1H, HCC=C), 4.36 - 4.12 (m, 2H, OCH₂CH₃), 3.51 (td, J = 10.6, 4.2 Hz, 1H, OCH-_{cyclohexyl}), 2.31 (pd, J = 7.0, 2.8 Hz, 1H, CHcyclohexyl), 2.09 – 2.00 (m, 1H, CH-cyclohexyl), 1.70 – 1.58 (m, 2H, CH-cyclohexyl), 1.40 – 1.24 (m, 6H, CH-isopropyl, CH-cyclohexyl and OCH₂CH₃), 1.11 – 1.03 (m, 22H, CH-cyclohexyl and TIPS), 0.90 (m, 7H, CH-cyclohexyl and 2 x CH₃isopropyl), 0.82 (d, J = 7.0 Hz, 3H, CH₃-methyl); ¹³C NMR (101 MHz, CDCl₃) δ 168.1, 101.0, 88.8, 78.4, 67.1, 61.9, 47.8, 39.8, 34.6, 31.7, 25.7, 23.7, 22.4, 21.0, 18.7, 16.6, 14.2, 11.3; Diaster 5k': R_f = 0.36 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.56 (s, 1H, HCC≡C), 4.16 – 4.00 (m, 2H, OCH₂CH₃), 3.21 (td, J = 10.6, 4.4 Hz, 1H, OCH-_{cyclohexyl}), 2.10 (m, 2H, CH-_{cyclohexyl}), 1.51 – 1.42 (m, 2H, CH-cyclohexyl), 1.24 – 1.05 (m, 6H, CH-isopropyl, CH-cyclohexyl and OCH2CH3), 0.90 (s, 22H, CH-cyclohexyl and TIPS), 0.73 (m, 7H, CH-cyclohexyl and 2 x CH₃-isopropyl), 0.60 (d, J = 6.9 Hz, 3H, CH₃-methyl) ¹³C NMR (101 MHz, CDCl₃) δ 168.1, 102.1, 88.6, 80.9, 69.1, 61.9, 48.3, 41.7, 34.4, 31.8, 25.5, 23.4, 22.3, 21.1, 18.7, 16.3, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2952 (s), 2925 (s), 2867 (s), 1766 (s), 1744 (m), 1463 (m), 1367 (m), 1274 (m), 1186 (s), 1107 (s), 1038 (s), 882 (s), 677 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₅H₄₆NaO₃Si⁺ 445.3108; Found 445.3116.

Ethyl 4-(triisopropylsilyl)-2-(((2R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)but-3-ynoate (5l)




Following general procedure A, starting from (-)-borneol (**4**I) (185 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5I**) (55:45 *dr* in the crude ¹H NMR) as a colorless oil (110 mg, 0.260 mmol, 87%). R_f = 0.45 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.75 and 4.68 (2 x s, 1H, HCC≡C), 4.33 – 4.15 (m, 2H, OCH₂CH₃), 4.06 – 3.92 (m, 1H, OCH), 2.25 – 1.99 (m, 2H, CH-_{bicyclo[2.2.1]heptan-2-yl}), 1.34 – 1.15 (m, 6H, CH-_{bicyclo[2.2.1]heptan-2-yl}), 1.12 – 0.94 (m, 21H, TIPS), 0.92- 0.88 (m, 3H, CH₃), 0.87 – 0.81 (m, 6H, 2 x CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.3, 168.0, 101.7, 101.5, 88.9, 88.5, 84.6, 83.7, 69.6, 68.7, 61.8, 61.7, 49.6, 49.5, 48.0, 45.2, 36.7, 36.0, 28.3, 28.2, 26.8, 26.7, 19.9, 19.0, 18.9, 18.7, 14.2, 14.0, 13.7, 11.3; Not all signals could be resolved. IR (v_{max}, cm⁻¹) 2943 (m), 2891 (m), 2866 (m), 2178 (w), 1765 (s), 1741 (m), 1464 (m), 1269 (m), 1184 (s), 1152 (s), 1091 (s), 1038 (s), 882 (s), 756 (s), 690 (s), 677 (s), 661 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₅H₄₄NaO₃Si⁺ 443.2952; Found 443.2966.

Ethyl 2-(((2*R*,3a*R*,6*R*,7*R*,8a*R*)-2,6,8,8-tetramethyloctahydro-1*H*-3a,7-methanoazulen-6-yl)oxy)-4- (triisopropylsilyl)but-3-ynoate (5m)




Following general procedure A, starting from (+)-cedrol (**4m**) (267 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5m**) (50:50 *dr* in the crude ¹H NMR) as a colorless oil (88 mg, 0.18 mmol, 60%). R_f = 0.36 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.84 and 4.82 (2 x s, 1H, *H*CC=C), 4.31 – 4.15 (m, 2H, OCH₂CH₃), 2.12 – 1.17 (m, 22H, CH-_{alphatic} and OCH₂CH₃), 1.10 – 0.93 (m, 24H, CH₃ and TIPS), 0.83 (d, *J* = 7.1 Hz, 3H, CHCH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.5, 168.9, 103.7, 103.1, 87.9, 87.3, 82.3, 82.3, 62.6, 62.2, 61.8, 61.7, 57.7, 57.1, 57.1, 57.0, 54.1, 54.1, 43.5, 43.4, 41.5, 41.4, 41.3, 37.2, 37.2, 32.9, 32.3, 31.5, 31.4, 29.1, 29.0, 27.7, 27.6, 25.5, 25.3, 25.0, 18.7, 15.8, 14.2, 11.3; Not all signals could be resolved. IR (v_{max}, cm⁻¹) 2943 (m), 2866 (m), 2178 (w), 1765 (s), 1741 (m), 1464 (m), 1283 (m), 1269 (m), 1184 (s), 1152 (s), 1091 (s), 1038 (s), 882 (s), 756 (s), 690 (s), 677 (s), 661 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₃₀H₅₂NaO₃Si⁺ 511.3578; Found 511.3582.

(E)-Ethyl 2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-4-(triisopropylsilyl)but-3-ynoate (5n)




Following general procedure B, starting from geraniol (**4n**) (211 µL, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5n**) as a colorless oil (72 mg, 0.17 mmol, 57%). R_f = 0.38 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 5.35 (ddt, *J* = 8.3, 7.0, 1.3 Hz, 1H, CHCH₂O), 5.08 (ddp, *J* = 7.0, 5.8, 1.4 Hz, 1H, (H₃C)₂C=CH), 4.77 and 4.68 (2 x s, 1H, HCC≡C), 4.34 – 4.18 (m, 4H, CHCH₂O and OCH₂CH₃), 2.16 – 2.01 (m, 4H, CH₂CH₂), 1.69 (m, 6H, 2 x CH₃), 1.60 (d, *J* = 1.4 Hz, 3H, CH₃), 1.30 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.13 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 142.5, 132.0, 124.0, 119.6, 100.6, 89.2, 67.7, 64.9, 62.0, 39.8, 26.4, 25.8, 18.7, 17.8, 16.6, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2959 (s), 2942 (s), 2893 (m), 2866 (s), 2174 (w), 1758 (s), 1463 (m), 1271 (m), 1189 (s), 1103 (s), 1040 (s), 883 (s), 677 (s), 662 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₅H₄₄NaO₃Si⁺ 443.2952; Found 443.2953.

Ethyl 2-(((8*R*,9*S*,10*R*,13*S*,14*S*,17*S*)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[a]phenanthren-17-yl)oxy)-4-(triisopropylsilyl)but-3-ynoate (50)




Adapted from general procedure A, starting from testosterone (**4o**) (260 mg, 0.900 mmol, 3 equiv.), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol, 1.00 equiv.), and ethyl 2-diazoacetate (**3a**) (1.00 mL, 0.60 mmol, 0.6 M in DCM, 2.00 equiv.), afforded the title compound (**5o**) (55:45 *dr* in the crude ¹H NMR) as a thick colorless oil (88 mg, 0.16 mmol, 53%). R_f = 0.45 (EtOAc/pentane 20:80), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 5.72 (s, 1H, *H*C=C), 4.76 – 4.65 (m, 1H, *H*CC=C), 4.34 – 4.14 (m, 2H, OCH₂CH₃), 3.77 – 3.60 (m, 1H, OCH), 2.50 – 2.16 (m, 4H, CH-_{alkyl}), 2.13 – 1.90 (m, 3H, CH-_{alkyl}), 1.88 – 1.77 (m, 1H, CH-_{alkyl}), 1.76 – 1.50 (m, 5H, CH-_{alkyl}), 1.50 – 0.77 (m, 36H, CH-_{alkyl}, CH₃, CH₃, OCH₂CH₃ and TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 199.7, 199.7, 171.4, 171.3, 168.0, 167.8, 124.0, 101.4, 101.3, 89.0, 88.6, 88.2, 88.2, 87.7, 69.2, 68.9, 61.9, 61.8, 54.0, 54.0, 50.7, 50.6, 43.1, 43.0, 38.8, 38.8, 37.6, 37.1, 35.9, 35.6, 34.1, 32.9, 31.7, 31.6, 28.2, 27.7, 23.5, 20.8, 20.7, 18.7, 17.5, 14.2, 11.8, 11.7, 11.3; Not all signals could be resolved. IR (v_{max}, cm⁻¹) 2919 (s), 2850 (m), 1759 (m), 1672 (m), 1659 (m), 1464 (m), 1268 (m), 1230 (m), 1188 (m), 1158 (m), 1115 (s), 1101 (s), 1016 (m), 882 (s), 779 (m), 679 (s); HRMS (ESI/LTQ-Orbitrap) m/z: [M+H]⁺ Calcd. for C₃₄H₅₅O₄Si⁺ 555.3864; Found 555.3859.

Ethyl 2-(((3a*R*,5*R*,5a*S*,8a*S*,8b*R*)-2,2,7,7-tetramethyltetrahydro-5*H*-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methoxy)-4-(triisopropylsilyl)but-3-ynoate (5p)



Following general procedure A, starting from 1,2:3,4-Di-*O*-isopropylidene- α -D-galactopyranose (**5p**) (312 mmol). $((3,3-bis(trifluoromethyl)-1\lambda^3-benzo[d][1,2]iodaoxol-1(3H)$ mg, 1.20 yl)ethynyl)triisopropylsilane (2a) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (3a) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5p**) (58:42 dr in the crude ¹H NMR) as a colorless oil (88 mg, 0.17 mmol, 56%). R_f = 0.62 (EtOAc/pentane 20:80), p-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 5.52 (d, J = 5.0 Hz, 1H, OCH_{anomer}), 4.94 and 4.89 (2 x s, 1H, HCC=C), 4.60 (ddd, J = 8.0, 3.7, 2.4 Hz, 1H, OCH), 4.34 – 4.15 (m, 4H, 2 x OCH and OCH₂CH₃), 4.11 – 3.96 (m, 1H, OCH), 3.96 – 3.79 (m, 2H, OCH₂), 1.56 – 1.52 (m, 3H, C(CH₃)₂), 1.45 – 1.41 (m, 3H, C(CH₃)₂), 1.35 – 1.31 (m, 6H, C(CH₃)₂), 1.29 (t, J = 7.1 Hz, 3H, OCH₂CH₃), 1.12 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 167.6, 109.4, 109.4, 108.8, 108.7, 100.1, 100.0, 96.5, 96.4, 89.7, 89.7, 71.4, 71.0, 70.8, 70.6, 69.6, 69.3, 67.5, 67.5, 67.0, 66.5, 62.0, 61.9, 29.7, 26.2, 26.1, 25.1, 24.7, 24.6, 18.7, 14.2, 11.2; Not all signals could be resolved. IR (v_{max}, cm⁻¹) 2941 (m), 2867 (w), 1757 (m), 1463 (w), 1382 (m), 1371 (m), 1255 (m), 1211 (s), 1169 (m), 1109 (s), 1069 (s), 1003 (s), 919 (m), 884 (m), 866 (m), 677 (m); HRMS (ESI/QTOF) m/z: $[M+Na]^+$ Calcd. for $C_{27}H_{46}NaO_8Si^+$ 549.2854; Found 549.2855.


Ethyl 2-(((2*R*,3*S*,5*R*)-5-(3-benzyl-5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3-(benzyloxy)tetrahydrofuran-2-yl)methoxy)-4-(triisopropylsilyl)but-3-ynoate (5q)



Β, from 3-benzyl-1-((2R,4S,5R)-4-(benzyloxy)-5-Following general procedure starting (hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (4q) (507 mg, 1.20 mmol), $((3,3-bis(trifluoromethyl)-1\lambda^3-benzo[d][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (2a)$ (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (3a) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (5q) (53:47 dr in the crude ¹H NMR) as a thick colorless oil (89 mg, 0.13 mmol, 43%). R_f = 0.38 (EtOAc/pentane 20:80), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.78 and 7.73 (2 x d, *J* = 1.4 Hz, 1H, HC=C), 7.52 - 7.44 (m, 2H, ArH), 7.41 - 7.20 (m, 8H, ArH), 6.48 (td, J = 8.2, 5.6 Hz, 1H, OCHN), 5.12 (s, 2H, NCH₂Ar), 4.78 (s, 1H, HCC=C), 4.57 (dd, J = 11.7, 4.1 Hz, 1H, OCH₂Ar), 4.49 (d, J = 11.7 Hz, 1H, OCH₂Ar), 4.37 – 4.16 (m, 4H, OCH₂CH₃, BnOCH and OCH₂CH), 4.09 – 4.01 (m, 0.5H, OCH₂CH), 3.94 - 3.80 (m, 1H, OCH₂CH), 3.70 - 3.61 (m, 0.5H, OCH₂CH), 2.46 (dddd, J = 13.4, 5.5, 3.9, 1.7 Hz, 1H, CH₂cvclic), 2.22 - 2.07 (m, 1H, CH₂-cvclic), 1.93 (dd, J = 3.7, 1.2 Hz, 3H, CH₃), 1.29 (td, J = 7.1, 1.4 Hz, 3H, OCH₂CH₃), 1.12 – 0.91 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 167.0, 166.9, 163.7, 163.7, 151.3, 151.3, 137.7, 137.7, 137.2, 137.2, 134.6, 134.4, 129.3, 129.3, 128.6, 128.5, 128.0, 127.7, 127.6, 127.6, 110.6, 110.4, 99.2, 99.0, 91.1, 90.5, 86.0, 85.9, 83.6, 83.6, 80.4, 80.1, 71.4, 71.3, 69.2, 69.1, 68.8, 68.7, 62.2, 44.6, 44.6, 37.6, 37.6, 18.7, 18.6, 14.2, 13.3, 13.2, 11.2; IR (v_{max}, cm⁻¹) 2947 (m), 2867 (m), 2175


(w), 1754 (m), 1701 (s), 1649 (s), 1458 (s), 1273 (m), 1200 (s), 1084 (s), 921 (m), 885 (m), 739 (m), 690 (s), 672 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₃₉H₅₂N₂NaO₇Si+ 711.3436; Found 711.3433.

Ethyl 2-((S)-3-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)-3-oxopropoxy)-4-(triisopropylsilyl)but-3ynoate (5r)




Following general procedure B, starting from *N*-carbobenzoxy-L-serine benzyl ester (**4r**) (395 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5r**) (53:47 *dr* in the crude ¹H NMR) as a colorless oil (65 mg, 0.11 mmol, 36%). R_f = 0.55 (EtOAc/pentane 20:80), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.27 (m, 10H, Ar*H*), 6.03 and 5.83 (2 x d, 8.4 Hz, 1H, N*H*), 5.28 – 5.05 (m, 4H, 2 x C*H*₂OAr), 4.85 – 4.76 (m, 1H, *H*CC≡C), 4.63 – 4.54 (m, 1H, NC*H*), 4.33 – 4.08 (m, 3H, OC*H*₂CH and OC*H*₂CH₃), 4.00 – 3.96 (m, 1H, OC*H*₂CH), 1.27 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.09 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 170.0, 170.0, 167.5, 167.3, 156.3, 156.2, 136.5, 136.4, 135.6, 135.5, 128.7, 128.7, 128.6, 128.6, 128.4, 128.4, 128.2, 128.2, 128.2, 128.2, 128.1, 98.8, 98.6, 91.1, 91.0, 69.0, 68.8, 68.0, 67.5, 67.4, 67.2, 67.1, 62.2, 62.1, 54.5, 54.5, 18.7, 14.2, 11.2; IR (v_{max}, cm⁻¹) 2943 (m), 2866 (m), 1746 (s), 1727 (s), 1509 (m), 1457 (m), 1336 (m), 1289 (m), 1197 (s), 1120 (s), 1053 (s), 882 (m), 735 (m), 696 (s), 677 (s), 664 (m); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₃₃H₄₅NNaO₇Si⁺ 618.2858; Found 618.2863.

Ethyl 7-chloro-2-(1-methylcyclopropoxy)hept-3-ynoate (5s)




Following general procedure A, starting from 1-methylcyclopropanol (**4s**) (68.0 µL, 1.20 mmol), 1-(5-chloropent-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2b**) (141 mg, 0.300 mmol), and ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5s**) as a colorless oil (27 mg, 0.10 mmol, 35%). R_f = 0.11 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.73 (t, *J* = 2.2 Hz, 1H, *H*CC≡C), 4.25 (q, *J* = 7.1 Hz, 2H, OCH₂CH₃), 3.63 (t, *J* = 6.4 Hz, 2H, CH₂Cl), 2.42 (td, *J* = 6.8, 2.2 Hz, 2H, C≡CCH₂), 1.96 (p, *J* = 6.6 Hz, 2H, CH₂CH₂Cl), 1.43 (s, 3H, CH₃), 1.31 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.07 – 1.00 (m, 1H, CH-_{cyclopropyl}), 0.93 – 0.85 (m, 1H, CH-_{cyclopropyl}), 0.49 – 0.37 (m, 2H, CH-_{cyclopropyl}); ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 85.8, 76.4, 67.5, 62.1, 60.2, 43.6, 31.1, 21.2, 16.4, 14.2, 13.9, 13.5; IR (v_{max}, cm⁻¹) 2963 (w), 2236 (w), 1759 (s), 1739 (s), 1445 (m), 1388 (m), 1291 (m), 1251 (s), 1187 (s), 1110 (m), 1075 (s), 1022 (s), 857 (m), 727 (m), 658 (m); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₃H₁₉ClNaO₃⁺ 281.0915; Found 281.0917.

Benzyl 2-(2-bromoethoxy)oct-3-ynoate (5t)




Following general procedure A, starting from 2-bromoethanol (**4t**) (85.0 µL, 1.20 mmol), 1-(hex-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[*d*][1,2]iodaoxole (**2c**) (135 mg, 0.300 mmol), and benzyl 2-diazoacetate (**3b**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5t**) as a colorless oil (92 mg, 0.26 mmol, 87%). R_f = 0.21 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.28 (m, 5H, ArH), 5.31 – 5.18 (m, 2H, CH₂Ar), 4.85 (t, *J* = 2.2 Hz, 1H, HCC=C), 4.04 – 3.87 (m, 2H, OCH₂CH₂Br), 3.50 (t, *J* = 6.5 Hz, 2H, CH₂Br), 2.24 (td, *J* = 7.0, 2.2 Hz, 2H, C=CCH₂), 1.55 – 1.44 (m, 2H, CH₂CH₂CH₃), 1.44 – 1.27 (m, 2H, CH₂CH₂CH₃), 0.89 (t, *J* = 7.3 Hz, 3H, CH₂CH₂CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 135.3, 128.7, 128.6, 128.3, 89.7, 72.8, 69.1, 68.4, 67.5, 30.4, 29.8, 22.0, 18.6, 13.7; IR (v_{max}, cm⁻¹) 2959 (w), 2933 (w), 1742 (m), 1256 (s), 1213 (s), 1180 (s), 1148 (s), 1110 (s), 963 (m), 947 (m), 926 (m), 756 (s), 729 (s), 698 (s), 680 (m); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₇H₂₁BrNaO₃⁺ 375.0566; Found 375.0571.

p-Tolyl 4-cyclopropyl-2-(2-(trimethylsilyl)ethoxy)but-3-ynoate (5u)



Following general procedure A, starting from 2-(trimethylsilyl)ethanol (**4u**) (172 μ L, 1.20 mmol), 1-(cyclopropylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2d**) (130 mg, 0.300 mmol), and *p*-tolyl 2-diazoacetate (**3c**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5u**) as a colorless oil (67 mg, 0.20 mmol, 68%). R_f = 0.34 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.13 (m, 2H, ArH), 7.05 – 6.98 (m, 2H, ArH), 4.85 (d, *J* = 2.0 Hz, 1H, HCC=C), 3.84 – 3.75 (m, 1H, OCH₂), 3.75 – 3.66 (m, 1H, OCH₂), 2.34 (s, 3H, ArCH₃), 1.37 – 1.27 (m, 1H, CH-_{cyclopropyl}), 1.09 – 1.00 (m, 2H, CH₂TMS), 0.86 – 0.72 (m, 4H, CH-_{cyclopropyl}), 0.04 (s, 9H, TMS); ¹³C NMR (101 MHz, CDCl₃) δ 167.0, 148.4, 135.9, 130.1, 121.0, 91.8, 68.8, 68.6, 66.8, 21.0, 18.2, 8.5, 8.5, -0.3, -1.3; IR (v_{max}, cm⁻¹) 2953 (w), 2895 (w), 2238 (w), 1775 (m), 1507 (m), 1248 (m), 1195 (s), 1166 (s), 1095 (s), 857 (s), 835 (s), 695 (m); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₉H₂₆NaO₃Si⁺ 353.1543; Found 353.1543.


2,6-Di-tert-butyl-4-methylphenyl 2-((3s,5s,7s)-adamantan-1-yloxy)-4-(triisopropylsilyl)but-3-ynoate (5v)



Following general procedure A, starting from 1-adamantanol (**4v**) (183 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and 1,3-di-*tert*-butyl-2-(diazomethyl)-5-methylbenzene (**3d**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5v**) as a viscous colorless oil (132 mg, 0.220 mmol, 74%). R_f = 0.43 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.11 (s, 2H, ArH), 5.18 (s, 1H,


*H*CC≡C), 2.31 (s, 3H, *CH*₃), 2.24 – 2.15 (m, 3H, 3 x *CH*), 2.01 – 1.87 (m, 6H, C(*CH*₂)₃), 1.73 – 1.59 (m, 6H, 3 x *CH*₂), 1.35 (m, 18H, 2 x *tBu*), 1.08 (s, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 168.1, 146.4, 142.3, 142.1, 134.8, 127.1, 127.1, 103.8, 89.0, 76.2, 62.5, 42.3, 36.4, 35.5, 35.5, 31.8, 31.7, 30.9, 21.7, 18.7, 18.7, 11.4; IR (v_{max} , cm⁻¹) 2912 (m), 2865 (m), 2251 (w), 2176 (w), 1760 (m), 1462 (m), 1421 (m), 1364 (m), 1271 (m), 1200 (m), 1183 (m), 1144 (m), 1104 (s), 1074 (s), 1018 (m), 909 (s), 883 (m), 733 (s), 677 (s); HRMS (ESI/QTOF) m/z: [M+K]⁺ Calcd. for C₃₈H₆₀KO₃Si⁺ 631.3943; Found 631.3958.

Furan-2-ylmethyl 4-(cyclohex-1-en-1-yl)-2-((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)but-3-ynoate (5w)




Following general procedure B, starting from 3-trimethylsilyl-2-propyn-1-ol (**4w**) (148 μ L, 1.20 mmol), 1-(cyclohex-1-en-1-ylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2e**) (119 mg, 0.300 mmol), and furan-2-ylmethyl 2-diazoacetate (**3e**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5w**) as a viscous colorless oil (36 mg, 0.10 mmol, 39%). R_f = 0.21 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 1.9, 0.9 Hz, 1H, Ar*H*), 6.49 – 6.42 (m, 1H, Ar*H*), 6.36 (dd, *J* = 3.3, 1.9 Hz, 1H, Ar*H*), 6.16 (p, *J* = 2.1 Hz, 1H, C=C*H*), 5.25 – 5.13 (m, 2H, OCH₂Ar), 5.08 (s, 1H, HCC=C), 4.37 (s, 2H, OCH₂C=C), 2.14 – 2.04 (m, 4H, CH-_{cyclohexenyl}), 1.68 – 1.51 (m, 4H, CH-_{cyclohexenyl}), 0.16 (s, 9H, TMS); ¹³C NMR (101 MHz, CDCl₃) δ 167.2, 148.8, 143.6, 137.6, 119.7, 111.4, 110.8, 100.0, 92.9, 90.0, 78.7, 67.5, 59.5, 56.7, 28.9, 25.8, 22.3, 21.5, -0.1; IR (v_{max}, cm⁻¹) 2934 (m), 2862 (w), 1753 (m), 1444 (w), 1251 (m), 1181 (m), 1090 (s), 1009 (m), 846 (s), 753 (m); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₁H₂₆NaO₄Si⁺ 393.1493; Found 393.1491.

2-Butoxy-4-(triisopropylsilyl)but-3-ynenitrile (5x)




Following general procedure A, starting from 1-butanol (**4x**) (110 µL, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and 2-diazoacetonitrile (**3f**) (1.20 mL, 0.600 mmol, 0.50 M in DCM), afforded the title compound (**5x**) as a colorless oil (57 mg, 0.19 mmol, 65%). R_f = 0.14 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 5.17 (s, 1H, HCC=C), 3.82 – 3.72 (m, 1H, OCH₂), 3.69 – 3.61 (m, 1H, OCH₂), 1.63 (tt, *J* = 8.3, 6.3 Hz, 2H, OCH₂CH₂), 1.47 – 1.35 (m, 2H, CH₂CH₃), 1.14 – 0.97 (m, 21H, TIPS), 0.93 (t, *J* = 7.4 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 114.9, 96.3, 91.8, 68.3, 58.0, 31.3, 19.3, 18.6, 13.9, 11.1; IR (v_{max}, cm⁻¹) 2945 (m), 2867 (m), 1740 (m), 1717 (m), 1464 (m), 1253 (m), 1091 (s), 1029 (m), 882 (s), 836 (m), 776 (m), 678 (s), 662 (s); HRMS (APCI/QTOF) m/z: [M+H]⁺ Calcd. for C₁₇H₃₂NOSi⁺ 294.2248; Found 294.2251.

Diethyl (3-(2-bromophenyl)-1-(3-oxobutoxy)prop-2-yn-1-yl)phosphonate (5y)




Following general procedure A, starting from 4-hydroxy-2-butanone (**4y**) (103 µL, 1.20 mmol), 1-((2-bromophenyl)ethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2f**) (165 mg, 0.300 mmol) and diethyl (diazomethyl)phosphonate (**3g**) (1.00 mL, 0.600 mmol, 0.60 M in DCM), afforded the title compound (**5y**) as a colorless oil (95 mg, 0.23 mmol, 76%). R_f = 0.17 (EtOAc/pentane 20:80), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (dd, *J* = 8.0, 1.3 Hz, 1H, ArH), 7.50 (dd, *J* = 7.6, 1.7 Hz, 1H, ArH), 7.30 – 7.23 (m, 1H, ArH), 7.20 (td, *J* = 7.7, 1.8 Hz, 1H, ArH), 4.73 (d, *J* = 19.4 Hz, 1H, HCC=C), 4.34 – 4.18 (m, 5H, 2 x POCH₂CH₃ and OCH₂), 3.92 (ddd, *J* = 9.6, 6.8, 5.9 Hz, 1H, OCH₂), 2.88 – 2.70 (m, 2H, CH₂COCH₃), 2.20 (s, 3H, COCH₃), 1.36 (tt, *J* = 7.0, 1.0 Hz, 6H, 2 x POCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 206.7, 133.9 (d, *J* = 5.2 Hz), 67.1 (d, *J* = 175.3 Hz), 66.0 (d, *J* = 12.5 Hz), 64.1 (dd, *J* = 11.1, 6.7 Hz), 43.6, 30.5, 16.7 (dd, *J* = 5.7, 3.8 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 14.3; IR (v_{max}, cm⁻¹) 2917 (w), 2849 (w), 1715 (m), 1469 (w), 1236 (m), 1165 (w), 1097 (m), 1021 (s), 977 (m), 756 (m); HRMS (APPI/LTQ-Orbitrap) m/z: [M+H]⁺ Calcd. for C₁₇H₂₃BrO₅P⁺ 417.0461; Found 417.0455.

Ethyl 7-((tert-butyldiphenylsilyl)oxy)-1-(cyclobutylmethoxy)hept-2-yne-1-sulfonate (5z)




Following general procedure A, starting from cyclobutanemethanol (**4z**) (113 µL, 1.20 mmol), ((6-(3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)hex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane (**2g**) (211 mg, 0.300 mmol), and ethyl diazomethanesulfonate (**3h**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5z**) as a colorless oil (132 mg, 0.240 mmol, 81%). R_f = 0.35 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.70 – 7.62 (m, 4H, Ar*H*), 7.49 – 7.33 (m, 6H, Ar*H*), 5.25 (t, *J* = 1.6 Hz, 1H, *H*CC≡C), 3.80 – 3.45 (m, 6H, 3 x OCH₂), 2.58 (hept, *J* = 7.4 Hz, 1H, OCH₂C*H*), 2.31 – 2.21 (m, 2H, CH₂-aliphatic), 2.13 – 2.00 (m, 2H, CH₂-aliphatic), 1.98 – 1.80 (m, 2H, CH₂-aliphatic), 1.80 – 1.59 (m, 6H, CH₂-aliphatic), 1.23 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.05 (s, 9H, tBu); ¹³C NMR (101 MHz, CDCl₃) δ 135.7, 134.1, 129.7, 127.8, 91.7, 86.5, 76.0, 69.4, 63.4, 61.0, 35.0, 31.9, 27.0, 25.3, 25.2, 25.0, 19.4, 18.7, 18.6, 15.2; IR (v_{max}, cm⁻¹) 2931 (m), 2859 (m), 2245 (w), 1428 (m), 1389 (w), 1359 (m), 1148 (m), 1108 (s), 1041 (s), 1008 (m), 740 (m), 701 (s), 613 (m); HRMS (APPI/LTQO) m/z: [M-C₂H₅O₃S]⁺ Calcd. for C₂₈H₃₇O₂Si⁺ 433.2557; Found 433.2543.

(3-(2-(Benzyloxy)ethoxy)-4,4,4-trifluorobut-1-yn-1-yl)benzene (5aa)




Following general procedure A, starting from 2-(benzyloxy)ethanol (**4aa**) (171 µL, 1.20 mmol), 1-(phenylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2h**) (141 mg, 0.300 mmol), and 2,2,2-trifluorodiazoethane (**3i**) (1.62 mL, 0.600 mmol, 0.37 M in DCM), afforded the title compound (**5aa**) as a colorless oil (73 mg, 0.22 mmol, 73%). R_f = 0.27 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.46 (m, 2H, ArH), 7.41 – 7.26 (m, 8H, ArH), 4.90 (q, *J* = 5.9 Hz, 1H, HCC≡C), 4.60 (s, 2H, CH₂Ar), 4.06 – 3.98 (m, 1H, OCH₂), 3.98 – 3.90 (m, 1H, OCH₂), 3.80 – 3.66 (m, 2H, CH₂OBn); ¹³C NMR (101 MHz, CDCl₃) δ 138.2, 132.2, 129.5, 128.6, 128.5, 127.9, 127.8, 122.7 (q, *J* = 281.8 Hz), 121.3, 88.8, 79.3 (q, *J* = 2.4 Hz), 73.5, 69.8 (q, *J* = 35.1 Hz), 69.4, 69.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.8; IR (v_{max}, cm⁻¹) 2871 (w), 1720 (w), 1703 (w), 1491 (w), 1454 (w), 1362 (w), 1272 (s), 1184 (s), 1141 (s), 1095 (s), 1028 (m), 756 (s), 690 (s); HRMS (APPI/LTQ-Orbitrap) m/z: [M]⁺ Calcd. for C₁₉H₁₇F₃O₂⁺ 334.1175; Found 334.1173.

Benzyl 3-((1,1,1-trifluoro-4-(triisopropylsilyl)but-3-yn-2-yl)oxy)azetidine-1-carboxylate (5ab)




Following general procedure B, starting from benzyl 3-hydroxyazetidine-1-carboxylate (**4ab**) (249 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and 2,2,2-trifluorodiazoethane (**3i**) (1.67 mL, 0.600 mmol, 0.36 M in DCM), afforded the title compound (**5ab**) as a colorless oil (86 mg, 0.18 mmol, 61%). R_f = 0.09 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.28 (m, 5H, Ar*H*), 5.10 (s, 2H, OC*H*₂Ar), 4.73 – 4.63 (m, 1H, OC*H*), 4.55 (q, *J* = 5.8 Hz, 1H, *H*CC≡C), 4.30 – 4.16 (m, 2H, NC*H*₂), 4.11 (ddd, *J* = 9.7, 4.4, 1.1 Hz, 1H, NC*H*₂), 4.01 (ddd, *J* = 9.8, 4.4, 1.2 Hz, 1H, NC*H*₂), 1.14 – 0.95 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 156.4, 136.6, 128.6, 128.2, 128.1, 122.1 (q, *J* = 281.9 Hz), 95.7, 93.5, 68.2 (q, *J* = 35.5 Hz), 67.7, 67.0, 57.9 – 56.3 (m), 18.6, 11.1; ¹⁹F NMR (376 MHz, CDCl₃) δ -77.0; IR (v_{max}, cm⁻¹) 2946 (m), 2867 (m), 1713 (s), 1456 (m), 1418 (s), 1352 (m), 1272 (m), 1181 (s), 1146 (s), 1093 (s), 1039 (m), 1001 (m), 882 (m), 736 (m), 697 (m), 680 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₄H₃₄F₃NNaO₃Si₊ 492.2152; Found 492.2164.

Triisopropyl(4,4,5,5,5-pentafluoro-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)pent-1-yn-1-yl)silane (5ac)




Following general procedure A, starting from (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl)methanol (4ac) (281 mg, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1λ³-benzo[d][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2i**) (165 mg, 0.300 mmol), and 3-diazo-1,1,1,2,2pentafluoropropane (3j) (1.67 mL, 0.600 mmol, 0.36 M in DCM), afforded the title compound (5ac) as a colorless oil (128 mg, 0.234 mmol, 78%). R_f = 0.40 (EtOAc/pentane 3:97), p-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.73 (m, 2H, ArH), 7.49 (dt, J = 7.7, 1.7 Hz, 1H, ArH), 7.44 – 7.34 (m, 1H, ArH), 4.88 (d, J = 11.7 Hz, 1H, CH₂O), 4.77 – 4.66 (m, 1H, CH₂O), 4.66 – 4.54 (m, 1H, HCC=C), 1.35 (s, 12H, 4 x CH₃), 1.19 – 0.96 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 135.3, 134.9, 134.9, 131.4, 129.4 (br s), 128.2, 118.8 (tq, J = 287.0, 35.0 Hz), 111.8 (qdd, J = 256.8, 36.3, 5.0 Hz), 95.9, 93.3, 84.0, 71.0, 67.3 (dd, J = 29.5, 24.8 Hz), 25.01 (d, J = 4.7 Hz), 18.6, 11.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -81.1, -119.9 (d, J = 273.9 Hz), -125.3 (d, J = 274.2 Hz); IR (v_{max}, cm⁻¹) 2945 (m), 2868 (m), 2181 (w), 1464 (w), 1434 (w), 1358 (s), 1321 (m), 1216 (s), 1198 (s), 1144 (s), 1099 (m), 1079 (m), 988 (m), 965 (m), 883 (m), 853 (m), 743 (m), 708 (s), 672 (s); HRMS (APCI/QTOF) m/z: [M+NH₄]⁺ Calcd. for C₂₇H₄₄BF₅NO₃Si⁺ 564.3098; Found 564.3115.

Ethyl 2-ethoxy-2-methyl-4-(triisopropylsilyl)but-3-ynoate (5ad)




Following general procedure B, starting from ethanol (4a) (70.0 µL, 1.20 mmol), ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (2a) (165 mg, 0.300 mmol), and ethyl 2-diazopropanoate (3k) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (5ad) as a colorless oil (42 mg, 0.13 mmol, 43%). R_f = 0.37 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.34 – 4.12 (m, 2H, (O)COCH₂), 3.81 (dq, *J* = 8.7, 7.1 Hz, 1H, OCH₂CH₃), 3.59 (dq, *J* = 8.9, 7.0 Hz, 1H, OCH₂CH₃), 1.67 (s, 3H, CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, (O)COCH₂CH₃), 1.25 (t, *J* = 7.0 Hz, 3H, OCH₂CH₃), 1.08 (s, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 171.0, 104.4, 87.9, 75.0, 62.4, 61.9, 27.7, 18.7, 15.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (m), 2868 (m), 1748 (s), 1460 (m), 1247 (m), 1196 (m), 1124 (s), 1065 (m), 881 (m), 670 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₈H₃₄NaO₃Si⁺ 349.2169; Found 349.2172.

(3-Ethoxy-4,4,4-trifluoro-3-phenylbut-1-yn-1-yl)triisopropylsilane (5ae)




Following general procedure B, starting from ethanol (**4a**) (70.0 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) (165 mg, 0.300 mmol), and (1-diazo-2,2,2-trifluoroethyl)benzene (**3l**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (**5ae**) as a colorless oil (66 mg, 0.17 mmol, 57%). R_f = 0.65 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.78 – 7.69 (m, 2H, Ar*H*), 7.45 – 7.37 (m, 3H, Ar*H*), 3.83 (dq, *J* = 8.9, 7.0 Hz, 1H, OCH₂CH₃), 3.44 (dq, *J* = 9.0, 7.0 Hz, 1H, OCH₂CH₃), 1.28 (t, *J* = 7.0 Hz, 3H, OCH₂CH₃), 1.21 – 0.95 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 134.4, 129.6, 128.3, 128.3, 123.1 (q, *J* = 285.2 Hz), 99.5, 93.2, 79.5 (q, *J* = 31.1 Hz), 61.7, 18.7, 15.4, 11.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -78.7; IR (v_{max}, cm⁻¹) 2947 (m), 2869 (m), 1460 (m), 1272 (m), 1180 (s), 1120 (m), 1068 (s), 952 (m), 884 (m), 763 (m), 708 (m), 672 (s); HRMS (ESI/QTOF) m/z: [M+Ag]⁺ Calcd. for C₂₁H₃₁AgF₃OSi⁺ 491.1142; Found 491.1136.

3-Ethoxy-3-((triisopropylsilyl)ethynyl)dihydrofuran-2(3H)-one (5af)





Following general procedure B, starting from ethanol (4a) (70.0 μ L, 1.20 mmol), ((3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (2a) (165 mg, 0.300 mmol), and 3-diazodihydrofuran-2(3*H*)-one (3m) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound (5af) as a colorless oil (44 mg, 0.14 mmol, 47%). R_f = 0.26 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.44 – 4.27 (m, 2H, OCH₂CH₂), 3.99 – 3.81 (m, 2H, OCH₂CH₃), 2.66 – 2.46 (m, 2H, OCH₂CH₂), 1.23 (t, *J* = 7.0 Hz, 3H, OCH₂CH₃), 1.13 – 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 171.8, 100.7, 91.9, 73.4, 65.4, 62.4, 38.9, 18.7, 15.5, 11.2; IR (v_{max}, cm⁻¹) 2944 (s), 2867 (m), 2170 (w), 1787 (s), 1463 (m), 1377 (m), 1224 (m), 1155 (s), 1060 (s), 1026 (s), 884 (m), 764 (m), 671 (s); HRMS (APCI/QTOF) m/z: [M+H]⁺ Calcd. for C₁₇H₃₁O₃Si⁺ 311.2037; Found 311.2030.

Ethyl 2-((triisopropylsilyl)ethynyl)tetrahydro-2H-pyran-2-carboxylate (5ag)




In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with $Cu(CH_3CN)_4PF_6$ (11.2 mg, 30.0 $((3,3-bis(trifluoromethyl)-1\lambda^3-benzo[d][1,2]iodaoxol-1(3H)$ μmol, 0.10 equiv.) and yl)ethynyl)triisopropylsilane (2a) (165 mg, 0.300 mmol). To the resulting solution was added a 0.6 M solution of ethyl 2-diazo-6-hydroxyhexanoate (3n) (0.60 mmol, 2.00 equiv.) in dry DCM in 1 h via seringe pump at 25 °C. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography (EtOAc/pentane) directly without further work-up, affording the title compound (5ag) as a colorless oil (21 mg, 62 µmol, 21%). R_f = 0.17 (EtOAc/pentane 3:97), panisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 4.26 (qq, J = 7.1, 3.6 Hz, 2H, OCH₂CH₃), 4.09 – 3.96 (m, 1H, OCH₂), 3.96 – 3.85 (m, 1H, OCH₂), 2.09 – 2.00 (m, 1H, CH-_{aliphatic}), 2.00 – 1.69 (m, 3H, CH-_{aliphatic}), 1.67 – 1.39 (m, 2H, CH-aliphatic), 1.29 (t, J = 7.2 Hz, 3H, OCH₂CH₃), 1.16 – 0.84 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 169.7, 102.9, 89.4, 74.4, 64.3, 62.0, 34.6, 25.0, 20.0, 18.7, 14.2, 11.3; IR (v_{max}, cm⁻¹) 2943 (s), 2865 (s), 2166 (w), 1762 (s), 1742 (s), 1464 (m), 1289 (m), 1255 (s), 1203 (s), 1149 (s), 1095 (m), 1066 (s), 1018 (s), 920 (m), 882 (s), 759 (m), 676 (s), 660 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₁₉H₃₄NaO₃Si⁺ 361.2169; Found 361.2174.





In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (5.59 mg, 15.0 μmol, 0.05 equiv.), 1-(cyclopropylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ benzo[d][1,2]iodaoxole (2d) (130 mg, 0.300 mmol, 1.00 equiv.) and tert-butyl carbamate (4ag) (45.7 mg, 0.390 mmol, 1.30 equiv.). The vial was capped, removed from the glovebox and dry DCM (5.35 mL) was added. To the resulting solution was added a 0.6 M solution of 1,4-dichloro-2-(1-diazo-2,2,2trifluoroethyl)benzene (**30**) (0.65 mL, 0.39 mmol, 1.30 equiv.) in dry DCM in 1 h via seringe pump at 25 °C. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography, using DCM as eluent, directly without further work-up affording the title compound (**5ah**) as a white solid (65 mg, 0.19 mmol, 62%). ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, J = 2.3 Hz, 1H, ArH), 7.33 – 7.29 (m, 1H, ArH), 7.29 – 7.24 (m, 1H, ArH), 4.88 (br s, 2H, NH₂), 1.42 (tt, J = 8.2, 5.2 Hz, 1H, CH-cyclopropyl), 0.94 – 0.83 (m, 4H, CH-cyclopropyl); ¹³C NMR (101 MHz, CDCl₃) 152.5, 133.3, 132.8, 132.1, 131.9, 131.1, 130.7, 122.5 (q, J = 285.8 Hz), 95.3, 77.9 (q, J = 33.3 Hz), 67.1, 8.8, 8.7, -0.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -77.5. The values of the NMR spectra are in accordance with reported literature data.¹

2-(4,4,4-Trifluoro-3-(4-methoxyphenethoxy)-3-(3-(trifluoromethyl)phenyl)but-1-yn-1-yl)thiophene (5ai)




Following general procedure B, starting from 4-methoxyphenethyl alcohol (**4ae**) (183 mg, 1.20 mmol), 1-(thiophen-2-ylethynyl)-3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2i**) (143 mg, 0.300 mmol), and 1-(1-diazo-2,2,2-trifluoroethyl)-3-(trifluoromethyl)benzene (**3p**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded the title compound (**5ai**) as an unseparable mixture with the corresponding O-H insertion product. The yield was estimated to be 73% by ¹⁹F NMR spectroscopy. A pure analytical sample was isolated by PTLC using toluene/acetone 95:5 as eluent. R_f = 0.31 (EtOAc/pentane 3:97), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H, ArH), 7.75 (d, *J* = 7.9 Hz, 1H, ArH), 7.69 – 7.63 (m, 1H, ArH), 7.48 (t, *J* = 7.8 Hz, 1H, ArH), 7.41 – 7.36 (m, 2H, ArH), ArH, 7.16 – 7.10 (m, 2H, ArH), 7.05 (dd, *J* = 5.1, 3.7 Hz, 1H, ArH), 6.86 – 6.80 (m, 2H, ArH), 4.04 – 3.95 (m, 1H, OCH₂), 3.79 (s, 3H, OCH₃), 3.59 – 3.51 (m, 1H, OCH₂), 2.94 (t, *J* = 6.9 Hz, 2H, CH₂Ar); ¹³C NMR (101 MHz, CDCl₃) δ 158.4, 135.4, 134.2, 131.7, 131.0 (q, *J* = 32.7 Hz), 130.4, 130.2, 129.1, 129.0, 127.4, 126.7 (q, *J* = 3.1 Hz), 125.2 (q, *J* = 3.5 Hz), 123.9 (q, *J* = 272.3 Hz), 122.8 (q, *J* = 285.9 Hz), 120.5, 114.0, 84.8, 84.7, 79.5 (q, *J* = 31.7 Hz), 67.6, 55.4, 35.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.6, -78.2; IR (v_{max}, cm⁻¹) 2931 (w), 2226 (w), 1515 (m),

¹ D. Dai, X. Long, A. Kulesza, J. Reichwagen, B. Luo and Y. Guo (Lonza Ltd), PCT Int. Appl. WO2012097510, 2012.


1329 (m), 1252 (m), 1178 (s), 1130 (s), 1082 (m), 1039 (m), 910 (w), 815 (w), 713 (m); HRMS (ESI/QTOF) m/z: $[M+H]^+$ Calcd. for $C_{24}H_{19}F_6O_2S^+$ 485.1004; Found 485.1006.

3-((2-([1,1'-Biphenyl]-4-yl)-1,1,1-trifluoro-5,5-dimethylhex-3-yn-2-yl)oxy)propanenitrile (5aj)



Following general procedure B, starting from 3-hydroxypropionitrile (**4af**) (81.0 μ L, 1.20 mmol), 1-(3,3-dimethylbut-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2j**) (135 mg, 0.300 mmol), and 4-(1-diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (**3q**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded the title compound **5aj** as a colorless oil (68 mg, 0.18 mmol, 59%). R_f = 0.24 (EtOAc/pentane 5:95), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.83 - 7.75 (m, 2H, Ar*H*), 7.69 - 7.57 (m, 4H, Ar*H*), 7.51 - 7.43 (m, 2H, Ar*H*), 7.42 - 7.35 (m, 1H, Ar*H*), 3.96 (dt, *J* = 9.4, 6.1 Hz, 1H, OC*H*₂), 3.67 (ddd, *J* = 9.4, 7.5, 6.1 Hz, 1H, OC*H*₂), 2.83 - 2.63 (m, 2H, C*H*₂CN), 1.37 (s, 9H, *t*Bu); ¹³C NMR (101 MHz, CDCl₃) δ 142.9, 140.3, 132.7, 129.0, 128.7, 127.9, 127.3, 127.3, 122.9 (q, *J* = 285.0 Hz), 117.4, 101.4, 79.4 (q, *J* = 31.8 Hz), 70.8, 60.4, 30.7, 28.0, 19.0; ¹⁹F NMR (376 MHz, CDCl₃) δ -78.84; IR (v_{max}, cm⁻¹) 2975 (w), 2251 (w), 1487 (m), 1290 (m), 1255 (m), 1175 (s), 1090 (s), 1007 (m), 943 (m), 884 (m), 836 (m), 766 (s), 738 (s), 697 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₃H₂₂F₃NNaO⁺ 408.1546; Found 408.1546.

2-(4-Bromophenyl)-8-(1,3-dioxoisoindolin-2-yl)-1,1,1-trifluorooct-3-yn-2-yl carbamate (5ak)



In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (5.59 mg, 15.0 μ mol, 0.05 equiv.), 2-(6-(3,3-bis(trifluoromethyl)-1 λ^3 -benzo[d][1,2]iodaoxol-1(3H)-yl)hex-5-yn-1yl)isoindoline-1,3-dione (2k) (179 mg, 0.300 mmol, 1.00 equiv.) and tert-butyl carbamate (4ag) (45.7 mg, 0.390 mmol, 1.30 equiv.). The vial was capped, removed from the glovebox and dry DCM (2.35 mL) was added. To the resulting solution was added a 0.6 M solution of 1-bromo-4-(1-diazo-2,2,2trifluoroethyl)benzene (**3r**) (0.65 mL, 0.39 mmol, 1.30 equiv.) in dry DCM in 1 h via seringe pump at 40 °C. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography, using EtOAc/pentane 33:67 as eluent, directly without further work-up affording the title compound (**5ak**) as a white solid (49 mg, 90 µmol, 31%). M.p. 117-118 °C; R_f = 0.54 (EtOAc/pentane 50:50), *p*-anisaldehyde; ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.79 (m, 2H, Ar*H*), 7.75 – 7.67 (m, 2H, Ar*H*), 7.56 - 7.45 (m, 4H, ArH), 5.00 (br s, 2H, NH2), 3.72 (t, J = 7.0 Hz, 2H, CH2N), 2.44 (t, J = 6.9 Hz, 2H, CH₂C=C), 1.92 – 1.79 (m, 2H, CH₂), 1.74 – 1.61 (m, 2H, CH₂); ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 152.4, 134.1, 133.1, 132.2, 131.7, 128.8, 124.1, 123.4, 122.2 (q, J = 284.2 Hz), 91.1, 72.7, 72.2 (q, J = 32.4 Hz), 37.5, 27.8, 25.4, 18.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -77.5; IR (ν_{max}, cm⁻¹) 2945 (m), 2870 (m), 2358 (w), 1461 (m), 1273 (m), 1180 (s), 1117 (s), 1068 (s), 763 (m), 711 (m), 674 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd. for C₂₃H₁₈BrF₃N₂NaO₄⁺ 545.0294; Found 545.0284.

4. Control experiments and mechanistic studies

a) Sequential addition of the alcohol and the EBX reagent (Scheme 5, Eq. (1)):

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (3.0 mg, 8.0 µmol, 0.20 equiv.). The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by EtOH (**4a**) (19 µL, 0.32 mmol, 8.00 equiv.). Ethyl diazoacetate (**3a**) (19 µL, 0.16 mmol, 4.00 equiv., 87%wt in DCM) was added dropwise and the resulting reaction mixture was stirred at room temperature for 1 h. After this time, an aliquot of the solution (0.40 mL) was taken and a ¹H NMR spectrum of the reaction mixture was recorded **(c)**. A solution of TIPS-EBX (**2a**) (22.0 mg, 40.0 µmol, 1.00 equiv.) in CD₂Cl₂ (0.40 mL) was added to the first solution and the reaction was continued for 1 h at room temperature. A ¹H NMR spectrum was recorded **(d)**.




Figure S1: ¹H NMR spectra of the sequential addition of EtOH (**4a**) and TIPS-EBX (**2a**).

No NMR signal of the desired three-component product **5a** appeared after the addition of TIPS-EBX (**2a**) to the already formed O-H insertion product **6a** in presence of the copper catalyst.

b) EBX reagent and diazo compound in presence of copper catalyst (Scheme 5, Eq. (2)):

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (3.0 mg, 8.0 μ mol, 0.10 equiv.) and TIPS-EBX **2a** (44 mg, 80 μ mol, 1.00 equiv.). The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by the dropwise addition of ethyl diazoacetate (**3a**) (19 μ L, 0.16 mmol, 4.00 equiv., 87%wt in DCM). Rapid evolution of nitrogen was

observed to occur. The reaction was continued for 1 h at room temperature. A ¹H NMR spectrum was recorded (c).




Figure S2: ¹H NMR spectra of the dimerization of EDA (3a) in presence of EBX (2a).

There was an obvious dimerization of ethyl diazoacetate (**3a**) to diethyl fumarate/maleate (**9**) in absence of alcohol. Approximately 10% of the EBX reagent **2a** was degraded to the precursor **13** and other unidentified by-products.


c) 1 H and 19 F NMR titration of EBX reagent with Cu(CH₃CN)₄PF₆:


In a N_2 filled glovebox, two differents oven-dried 10 mL microwave vials were prepared with the following solutions:

(1): 0.1 M solution of TIPS-EBX (2a) (110 mg, 2.00 mmol) in CD₂Cl₂ (2.0 mL).


(2): 0.1 M solution of $Cu(CH_3CN)_4PF_6$ (74.5 mg, 2.00 mmol) in CD_2Cl_2 (2.0 mL).

TIPS-EBX (**2a**) (200 μ L of solution (1), 0.02 mmol, 1.00 equiv.) was then stirred for 1h at room temperature with differents equivalent of Cu(CH₃CN)₄PF₆ (gradient from 0 μ L of solution (2), 0.00 mmol, 0.00 equiv. to 600 μ L of solution (2), 0.06 mmol, 3.00 equiv.) All solutions were adjusted with CD₂Cl₂ (600 μ L to 0 μ L) before the addition of the solution (2) to have V_{tot} = 800 μ L.





8.60 8.55 8.50 8.45 8.40 8.35 8.30 8.25 8.20 8.15 8.10 8.05 8.00 7.95 7.90 7.85 7.80 7.75 7.70 7.65 7.60 7.55 7.50 7.4¹ **Figure S3:** ¹H NMR titration of the EBX reagent with Cu(CH₃CN)₄PF₆.



Progressive shifts of the aromatic ¹H^a were observed upon addition of the copper salt, with a significant diminution after one equivalent. Others ¹H signals were less influenced by the presence of the Cu salt. Minor shift of ¹⁹F signal of **2a** was observed (The new doublet appearing comes from the PF₆⁻).

d) 13 C NMR spectrum of the complexation of the EBX reagent with Cu(CH₃CN)₄PF₆:

Samples (a) (0.00 equiv.) and (e) (1.00 equiv.) from the titration experiment were submitted to 13 C NMR analysis.





Figure S5: ¹³C NMR spectrum of the complexation of the EBX reagent and $Cu(CH_3CN)_4PF_6$.

Major changes of ${}^{13}C^a$ ($\Delta\delta$ = 0.7 ppm, 71.1 Hz) and ${}^{13}C^b$ ($\Delta\delta$ = 3.4 ppm, 339.5 Hz) were observed. Other ${}^{13}C$ signals remained almost unchanged in presence of the Cu salt.

e) Mixing EtOH with Cu(CH₃CN)₄PF₆:

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with Cu(CH₃CN)₄PF₆ (30 mg, 0.080 mmol, 1.00 equiv.). The vial was capped, removed from the glovebox and CD₂Cl₂ (0.80 mL) was added, followed by the addition of EtOH (**4a**) (19 μ L, 0.32 mmol, 4.00 equiv.). The resulting reaction mixture was stirred at room temperature for 1 h. A ¹H NMR spectrum was recoreded (**c**). The solvent was then removed under reduced pressure and a new ¹H NMR spectrum was recorded in CD₂Cl₂ (**d**).



No shift of ¹H signals of ethanol or $Cu(CH_3CN)_4PF_6$ were observed. When the reaction mixture was evaporated, the initial copper salt was recovered.

f) Cu-carbene trapping through cyclopropanation (Scheme 5, Eq (3)):

In a N₂ filled glovebox, an oven-dried 10 mL microwave vial was charged with $Cu(CH_3CN)_4PF_6$ (3.0 mg, 8.0 µmol, 0.10 equiv.) and TIPS-EBX **2a** (44 mg, 80 µmol, 1.00 equiv.). The vial was capped, removed from the glovebox and CD_2Cl_2 (0.80 mL) was added, followed by the addition of ethanol (**4a**) (19 µL, 0.32 mmol, 4.00 equiv.) and styrene (37 µL, 0.32 mmol, 4.00 equiv.). A solution of ethyl diazoacetate (**3a**) in DCM (133 µL, 80 µmol, 1.00 equiv., 0.6 M) was slowly added in 1 h via seringe pump. At the end of the addition, the reaction was continued 1 h at room temperature. ¹H NMR spectrum of the reaction mixture was recoreded (**d**). For comparison, control experiments missing the EBX reagent (spectrum (**c**)), ethanol (spectrum (**b**)) and EBX + ethanol (spectrum (**a**)) were done.





Figure S7: ¹H NMR spectrum of the competitive cyclopropanation with styrene.

The three-component product **5a** was the major product observed (62%). The conversion of TIPS-EBX (**2a**) was 62%. A detectable amount of cyclopropane **12** was observed (21%). The O-H insertion product **6a** was also detected (10%). In absence of EtOH, cyclopropane **12** was the major product formed (spectrum (**a**) and (**b**)). The O-H insertion product **6a** was predominant (83%) over the cyclopropane **12** (16%) when EtOH (4.00 equiv.) and styrene (4.00 equiv.) were in competition (spectrum (**c**)).


g) Effect of *t*BuBOX ligand (Scheme 5, Eq (4)):



In a N₂ filled glovebox, a catalytic solution was prepared by mixing Cu(CH₃CN)₄PF₆ (16.8 mg, 45.0 μ mol, 0.15 equiv.) and (*S*,*S*)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline) (**9**) (14.6 mg, 50.0 μ mol, 0.17 equiv.) in dry DCM (3.00 mL) at room temperature for 1 h.

2.00 mL of the catalytic solution was added to an oven-dried 10 mL microwave vial previously charged with TIPS-EBX **2a** (165 mg, 0.3 mmol, 1.00 equiv.) under N_2 atmosphere followed by benzyl alcohol (**4b**)

(124 μ L, 1.20 mmol, 4.00 equiv.). To the resulting solution was added ethyl 2-diazoacetate (**3a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM) in 1 h *via* seringe pump at 25 °C. The system was mainted isobaric with a filled balloon with N₂. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was analyzed by ¹H NMR. Ethyl 2-(benzyloxy)-4-(triisopropylsilyl)but-3-ynoate (**5b**) was formed in 30% yield in the crude reaction mixture. The crude product was purified by column chromatography using EtOAc/pentane 3:97 as eluent to afford ethyl 2-(benzyloxy)-4-(triisopropylsilyl)but-3-ynoate (**5b**) (23 mg, 0.06 mmol, 20%) as a colorless oil. Chiral HPLC conditions: ee = <1%; Chiralpak IA 98:2 Hexane/iPrOH, 1.0 mL/min, 60 min. tr (1) = 6.051 min. and tr (2) = 6.416 min. λ = 254 cm⁻¹.




Benzyl alcohol (4b) was used instead of ethanol (4a) to facilitate HPLC analysis of the enantioselectivity.


5. Synthesis of diazo-compounds

CAUTION: Diazo compounds are toxic and potentially explosive and should be handled with care in a well-ventilated hood.²

Ethyl 2-diazoacetate (**3a**) and benzyl 2-diazoacetate (**3b**) were directly purchased from Sigma Aldrich.



p-Tolyl 2-diazoacetate (3c)




Bromoacetyl bromide (**18**) (1.31 mL, 15.0 mmol, 1.50 equiv) was added to a stirred solution of *p*-cresol (**17**) (1.08 g, 10.0 mmol, 1.00 equiv) and pyridine (1.61 mL, 20.0 mmol, 2.00 equiv) in acetonitrile (50 mL) at 0 °C over 10 minutes. The mixture was stirred for further 5 minutes at 0 °C and then quenched with water (30 mL). The reaction mixture was extracted with dichloromethane (3 x 30 mL). The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 5:95 as eluent to afford *p*-tolyl 2-bromoacetate (**19**) as a colorless oil (2.1 g, 9.2 mmol, 92%). ¹H NMR (400 MHz, CDCl₃) δ 7.23 – 7.15 (m, 2H, Ar*H*), 7.05 – 6.95 (m, 2H, Ar*H*), 4.04 (s, 2H, CH₂), 2.35 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 166.2, 148.4, 136.2, 130.2, 120.9, 25.7, 21.0. The values of the NMR spectra are in accordance with reported literature data.³

Following a reported procedure, *N*,*N*'-Ditosylhydrazine (3.40 g, 10.0 mmol, 2.00 equiv) was added to a solution of *p*-tolyl 2-bromoacetate (**19**) (1.15 g, 5.00 mmol, 1.00 equiv) in tetrahydrofuran (20 mL) and the mixture was cooled to 0 °C. 1,8-Diazabicycloundec-7-ene (3.8 mL, 25 mmol, 5.0 equiv) was added dropwise over 20 minutes at 0 °C. The reaction was stirred 2 h at 0 °C before being quenched by a saturated aqueous NaHCO₃ solution (30 mL). The reaction mixture was extracted with diethyl ether (3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 5:95 as eluent to afford *p*-tolyl 2-diazoacetate (**3c**) as a yellow oil (0.450 g, 2.55 mmol, 51%). R_f = 0.33 (EtOAc/pentane 5:95), KMnO₄; ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.14 (m, 2H, Ar*H*), 7.03 – 6.98 (refm, 2H, Ar*H*), 4.95 (br s, 1H, *CHN*₂), 2.34 (s, 3H, *CH*₃); ¹³C NMR (100 MHz, CDCl3) δ 148.4, 135.7, 130.1, 121.5, 46.9, 21.0; IR (v_{max}, cm⁻¹) 3115 (w), 2112 (s), 1699 (s), 1508 (m), 1364 (s), 1342 (s), 1193 (s), 1167 (s), 1143 (s), 923 (m), 831 (m), 728 (m); HRMS (ESI) calcd. for C₉H₉N₂O₂⁺ [M+H]⁺ 177.0659; found 177.0656. One carbon was not resolved at 100 MHz.

² S. P. Green, K. M. Wheelhouse, A. D. Payne, J. P. Hallett, P. W. Miller and J. A. Bull, *Org. Process Res. Dev.* **2020**, *24*, 67.

³ G. Himbert, D. Fink and K. Diehl, Chem. Ber. 1988, 121, 431.


2,6-Di-tert-butyl-4-methylphenyl 2-diazoacetate (3d)



Following a slightly modified procedure,⁴ a mixture of 2,6-di-*tert*-butyl-4-methylphenol (**20**) (5.51 g, 25.0 mmol, 1.00 equiv), 2,2,6-trimethyl-4*H*-1,3-dioxin-4-one (**21**) (3.32 mL, 25.0 mmol, 1.00 equiv), and xylene (5 mL) was stirred at 140 °C for 1.5 h. After cooling to room temperature, the reaction mixture was directly loaded on silica and was purified by column chromatography using EtOAc/pentane 2:98 as eluent to afford 2,6-di-*tert*-butyl-4-methylphenyl 3-oxobutanoate (**22**) as a white solid (5.77 g, 19.0 mmol, 76%). ¹H NMR (400 MHz, CDCl₃) δ 12.08 (s, 0.22H, OH of enol form), 7.31 – 7.24 (m, 1H, ArH of enol and keto form), 7.24 – 7.18 (m, 2H, ArH of enol and keto form), 5.38 (s, 0.2H, vinyl H of enol form), 3.81 (s, 1.56H, CH₃COCH₂ of keto form), 3.03 (m, 2H, 2 x CH(CH₃)₂ of enol and keto form), 2.41 (s, 2.32H, CH₃COCH₂ of keto form), 2.08 (s, 0.6H, CH₃ of enol form), 1.28 – 1.21 (m, 12H, 2 x CH(CH₃)₂); ¹³C NMR (101 MHz, CDCl₃), Enol form: δ 197.7, 171.5, 144.5, 140.5, 126.5, 123.9, 88.7, 23.7, 22.7, 21.4; ¹³C NMR (101 MHz, CDCl₃), Keto form: δ 199.9, 165.7, 145.1, 140.2, 126.8, 124.0, 49.6, 30.4, 27.4, 27.3. The values of the NMR spectra are in accordance with reported literature data.⁵

Following a slightly modified procedure,⁴ to a solution of 2,6-di-*tert*-butyl-4-methylphenyl 3oxobutanoate (**22**) (5.48 g, 18.0 mmol, 1.00 equiv) in MeCN (22 mL) was added triethylamine (3.26 mL, 23.4 mmol, 1.30 equiv). The reaction mixture was cooled in an ice bath and a solution of tosyl azide (3.90 g, 19.8 mmol, 1.1 equiv) in MeCN (22 mL) was added slowly. The reaction mixture was allowed to warm to room temperature and stirred for 20 h. 8% aqueous KOH solution (90 mL) was added and stirred vigorously for 4 h. The reaction mixture was diluted with water (50 mL) and extracted with diethyl ether (3 x 100 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using Et₂O/pentane 2:98 as eluent to afford 2,6-di-*tert*-butyl-4-methylphenyl 2-diazoacetate (**3d**) as a yellow solid (4.80 g, 16.6 mmol, 92%). ¹H NMR (400 MHz, CDCl₃) δ 7.12 (s, 2H, ArH), 5.00 (s, 1H, CHN₂), 2.32 (s, 3H, ArCH₃), 1.36 (s, 18H, 2 x tBu); ¹³C NMR (101 MHz, CDCl₃) δ 166.3, 145.1, 142.4, 134.8, 127.0, 47.3, 35.3, 31.5, 21.5. The values of the NMR spectra are in accordance with reported literature data.⁶

Furan-2-ylmethyl 2-diazoacetate (3e)



Following a slightly modified procedure,⁷ to a solution of *p*-toluenesulfonylhydrazone of glyoxylic acid chloride (**24**) (1.30 g, 5.00 mmol, 1.00 equiv.) in CH₂Cl₂ (10 mL) were added furfuryl alcohol (**23**) (475 μ L, 5.50 mmol, 1.10 equiv.) and then DBU (1.89 mL, 12.5 mmol, 2.50 equiv.) dropwise at 0 °C. After

⁴ P. Müller and P. Polleux, *Helv. Chim. Acta* **1994**, *77*, 645.

⁵ D. P. Hari and J. Waser, J. Am. Chem. Soc., 2017, **139**, 8420.


⁶ M. P. Doyle, V. Bagheri, T. J. Wandless, N. K. Harn, D. A. Brinker, C. T. Eagle and K. L. Loh, *J. Am. Chem. Soc.* **1990**, *112*, 1906.

⁷ T. Hashimoto, N. Uchiyama and K. Maruoka, J. Am. Chem. Soc. **2008**, 130, 14380.

stirring for 2 h at the same temperature, the reaction was stirred 30 min at room temperature and then poured into saturated NH₄Cl solution (10 mL). The organic layer was then extracted with CH₂Cl₂ (3 x 10 mL), washed with brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 3:97 as eluent to afford furan-2-ylmethyl 2-diazoacetate (**3e**) as a yellow oil (534 mg, 3.21 mmol, 64%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 1.9, 0.9 Hz, 1H, Ar*H*), 6.42 (dd, *J* = 3.3, 0.8 Hz, 1H, Ar*H*), 6.36 (dd, *J* = 3.3, 1.8 Hz, 1H, Ar*H*), 5.14 (s, 2H, CH₂O), 4.78 (br s, 1H, CN₂*H*); ¹³C NMR (101 MHz, CDCl₃) δ 166.6, 149.5, 143.5, 111.0, 110.7, 58.3, 46.5. The values of the NMR spectra are in accordance with reported literature data.⁸

2-Diazoacetonitrile (3f)


CAUTION: This diazo compound is reported to be explosive at high concentration.



Following a reported procedure,⁹ to a suspension of 2-aminoacetonitrile sulfate (**25**) (3.70 g, 24.0 mmol, 1.00 equiv.) in DCM (28 mL) at -10 °C was cautiously added dropwise an aqueous solution of sodium nitrite (4.97 g, 72.0 mmol, 3.00 equiv.) in distilled water (22 mL) at such a rate that the temperature of the reaction did not rise above 0 °C. During the addition effervescence was observed. After the complete addition, the reaction was allowed to stir for 30 min at 0 °C. The organic layer was separated and the aqueous layer further extracted with DCM (20 mL). The combined organic layers were washed with 1% aqueous NaHCO₃ solution (10 mL), dried over MgSO₄, filtered and stored at - 18 °C.

The concentration of the solution was assumed to be 0.5 M of diazoacetonitrile (**3f**) in DCM and was used immediately without further purification.

Diethyl (diazomethyl)phosphonate (3g)



Following a reported procedure,¹⁰ a mixture of diethyl (2-oxopropyl)phosphonate (**26**) (1.15 mL, 6.00 mmol, 1.00 equiv), tosyl azide (1.3 g, 6.6 mmol, 1.10 equiv) and triethylamine (6 mL) was stirred at room temperature for 18 h. After evaporation of the triethylamine under reduced pressure, the residue was dissolved in diethyl ether (50 mL). The precipitate was filtered off, the filtrate was evaporated and the residue was purified by column chromatography using EtOAc/pentane 50:50 as eluent affording the corresponding diethyl (1-diazo-2-oxopropyl)phosphonate (**27**) as a yellow oil (0.810 g, 3.68 mmol, 61%). ¹H NMR (400 MHz, CDCl₃) δ 4.04 – 4.19 (m, 4H, 2 x CH₂CH₃) 2.19 (s, 3H, CH₃), 1.30 (t, *J* = 7.0 Hz, 6H, 2 x CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 190.1 (d, *J* = 13.2 Hz), 63.4 (d, *J* = 5.6 Hz), 27.1, 16.0 (d, *J* = 6.8 Hz). The values of the NMR spectra are in accordance with reported literature data.⁵


⁸ S. Bew, P.-A. Ashford and D. Bachera, *Synthesis* **2013**, *45*, 903.

⁹ J. Dunn and A. P. Dobbs, *Tetrahedron* **2015**, *71*, 7386.

¹⁰ S. Chanthamath, S. Ozaki, K. Shibatomi and S. Iwasa, Org. Lett. **2014**, *16*, 3012.


To a solution of diethyl (1-diazo-2-oxopropyl)phosphonate (**27**) (694 mg, 3.15 mmol, 1.00 equiv) in MeOH (9.0 mL) was added Na₂CO₃ (401 mg, 3.78 mmol, 1.20 equiv). The mixture was stirred at room temperature for 15 min. The precipitate was filtered off, the filtrate was evaporated and the residue was purified by column chromatography using EtOAc/pentane 50:50 as eluent affording the corresponding diethyl (diazomethyl)phosphonate (**3g**) as a yellow oil (533 mg, 2.99 mmol, 95%). ¹H NMR (400 MHz, CDCl₃) δ 4.17 – 4.08 (m, 4H, 2 x CH₂CH₃), 3.75 (d, *J* = 11.1 Hz, 1H, CHN₂), 1.34 (td, *J* = 7.1, 0.7 Hz, 6H, 2 x CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 62.6 (d, *J* = 5.3 Hz), 16.1 (d, *J* = 6.9 Hz). The values of the NMR spectra are in accordance with reported literature data. One carbon was not resolved at 101 MHz.⁵

Ethyl diazomethanesulfonate (3h)



Following a reported procedure,¹¹ to a solution of ethyl methanesulfonate (28) (1.86 g, 15.0 mmol, 1.00 equiv) in dry THF (50 mL) was added a 1 M LiHMDS solution in hexane (18 mL, 18 mmol, 1.2 equiv) at -78 °C. After stirring the reaction mixture for 30 min at this temperature, 2,2,2-trifluoroethyl trifluoroacetate (29) (2.4 mL, 18 mmol, 1.2 equiv) was added rapidly in one portion via syringe. After 10 min, the reaction mixture was poured into a solution of diethyl ether (20 mL) and 5% HCl (50 mL). The mixture was extracted with diethyl ether (3 x 50 mL), washed with brine (50 mL), dried over MgSO₄, filtered and concentrated under reduced pressure to give a yellow oil. The resulting ethyl 3,3,3trifluoro-2-oxopropane-1-sulfonate (30) was immediately dissolved in dry MeCN (30 mL). To this solution was added p-ABSA (4.32 g, 18.0 mmol, 1.20 equiv), Et₃N (2.5 mL, 18 mmol, 1.2 equiv), and water (0.27 mL, 15 mmol, 1.0 equiv). After stirring the reaction mixture overnight at room temperature, the solvent was removed under reduced pressure and the residue was filtered on short plug of silica gel and washed with a mixture of ethyl acetate (100 mL) and hexane (100 mL). The filtrate was concentrated under vacuum and the residue was purified by column chromatography using EtOAc/pentane 10:90 as eluent to afford ethyl diazomethanesulfonate (3h) as a yellow oil (0.9 g, 6 mmol, 40%). ¹H NMR (400 MHz, CDCl₃) δ 5.25 (s, 1H, CHN₂), 4.26 (q, J = 7.1 Hz, 2H, CH₂CH₃), 1.41 (t, J = 7.1 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 67.4, 52.4, 14.6. The values of the NMR spectra are in accordance with reported literature data.¹¹

2,2,2-Trifluorodiazoethane (3i)



Following a reported procedure,¹² under argon, 2,2,2-trifluoroethanamine hydrochloride (**31**) (0.678 g, 5.00 mmol, 1.00 equiv) and sodium nitrite (0.379 g, 5.50 mmol, 1.10 equiv) were dissolved in degassed CH_2Cl_2 (10 mL). Degassed water (1.00 mL, 55.5 mmol, 11.1 equiv) was added slowly at 0 °C. The solution was stirred for 2 h at 0 °C and 1 h at room temperature. The aqueous layer was frozen in the freezer overnight (-18 °C) and the organic layer was dried over a plug of potassium carbonate, transferred into a vial, sealed and stored at - 18 °C. The concentration of the obtained solution was

¹¹ Ye T. and Zhou C., New J. Chem. **2005**, 29, 1159.

¹² S. Hyde, J. Veliks, B. Liégault, D. Grassi, M. Taillefer and V. Gouverneur, Angew. Chem. Int. Ed., 2016, 55, 3785.


determined to be 0.37 M by ¹⁹F NMR analysis (according to an internal reference, PhCF₃). ¹⁹F NMR (377 MHz, CH₂Cl₂) δ -55.56. The values of the NMR spectra are in accordance with reported literature data.

3-Diazo-1,1,1,2,2-pentafluoropropane (3j)

$$\begin{array}{ccc} H_2 N & C_2 F_5 & \underbrace{NaNO_2, H_2 O}_{CH_2 CI_2} & H & C_2 F_5 \end{array}$$


Under argon, 2,2,2-trifluoroethanamine hydrochloride (**32**) (0.928 g, 5.00 mmol, 1.00 equiv) and sodium nitrite (0.379 g, 5.50 mmol, 1.10 equiv) were dissolved in degassed CH_2Cl_2 (10 mL). Degassed water (1.00 mL, 55.5 mmol, 11.1 equiv) was added slowly at 0 °C. The solution was stirred for 2 h at 0 °C and 1 h at room temperature. The organic layer was isolated, dried over MgSO₄, transferred into a vial, sealed and stored at - 18 °C. The concentration of the obtained solution was determined to be 0.36 M by ¹⁹F NMR analysis (according to an internal reference, PhCF₃). ¹⁹F NMR (377 MHz, CH₂Cl₂) δ - 88.96 - -89.01 (m), -110.98 - -111.03 (m).

Ethyl 2-diazopropanoate (3k)



Following a modified reported procedure,¹³ DBU (1.8 mL, 12 mmol, 3.0 equiv) was added slowly to a stirred solution of ethyl 2-methylacetoacetate (**33**) (0.60 mL, 4.0 mmol, 1.0 equiv) and *p*-ABSA (1.4 g, 6.0 mmol, 1.5 equiv) in MeCN (80 mL) at 0 °C. The reaction mixture was then allowed to warm to room temperature. After stirring for 12 h, the reaction mixture was quenched with 1 M HCl (8 mL), and extracted with hexane (3 x 40 mL). The organic layers were combined, washed with a saturated solution of NaHCO₃ (40 mL), brine (40 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using Et₂O:pentane 2:98 as eluent affording the corresponding ethyl 2-diazopropanoate (**3k**) as a yellow oil (241 mg, 1.88 mmol, 47%). ¹H NMR (400 MHz, CDCl₃) δ 4.20 (q, *J* = 7.1 Hz, 2H, *CH*₂CH₃), 1.94 (s, 3H, N₂CCH₃), 1.25 (t, *J* = 7.1 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 167.9, 60.7, 14.5, 8.4. The values of the NMR spectra are in accordance with reported literature data.¹⁴ One carbon was not resolved at 101 MHz.

(1-Diazo-2,2,2-trifluoroethyl)benzene (3I)



2,2,2-Trifluoroacetophenone (**34**) (702 μ L, 5.00 mmol, 1.05 equiv.) was added to EtOH (18.8 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (880 mg, 4.76 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid.


¹³ T. Hashimoto, Y. Naganawa and K. Maruoka, J. Am. Chem. Soc. **2011**, 133, 8834.

¹⁴ L. Huang and W. D. Wulff, J. Am. Chem. Soc. **2011**, 133, 8892.

Then, pentane (100 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.

procedure,18 Following а reported 4-methyl-N'-(2,2,2-trifluoro-1phenylethylidene)benzenesulfonohydrazide (35) was disolved in a 0.4 M solution of potassium hydroxide (561 mg, 5.00 mmol, 2.00 equiv.) in MeOH (25.0 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (15 mL). The crude product was extracted with pentane (3 x 20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using pentane as eluent to afford (1-diazo-2,2,2-trifluoroethyl)benzene (3I) as a volatile orange oil (344 mg, 1.85 mmol, 37%). The compound was kept as a 0.6 M solution in DCM at -18 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.36 (m, 2H, ArH), 7.23 – 7.17 (m, 1H, ArH), 7.13 – 7.05 (m, 2H, Ar*H*); ¹³C NMR (101 MHz, CDCl₃) δ 129.6, 126.1, 125.8 (q, *J* = 269.4 Hz), 123.7, 122.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -57.4. One carbon was not resolved at 101 MHz. The values of the NMR spectra are in accordance with reported literature data.¹⁸


3-Diazodihydrofuran-2(3H)-one (3m)



Following a reported procedure,¹⁵ sodium azide (2.42 g, 37.2 mmol, 4.00 equiv), sodium hydroxide (78 mL, 2 M in water), tetrabutylammonium bromide (30.0 mg, 93.0 µmol, 0.01 equiv), and pentane (40 mL) were mixed in a 250 mL round-bottom flask with magnetic stirring bar open to the air and allowed to cool to 0 °C. With vigorous stirring, Tf₂O (3.10 mL, 18.6 mmol, 2.00 equiv) was added dropwise. After 10 min, a solution of 2-acetyl-butyrolactone (36) (1.00 mL, 9.30 mmol, 1.00 equiv) in MeCN (35 mL) was poured into the round-bottom flask through a funnel, followed by additional MeCN (10 mL) to complete the transfer. The initially colorless reaction mixture immediately turned yellow. After allowing to stir for 30 min at 0 °C, the mixture was diluted with ice water (25 mL) and EtOAc (25 mL) and transferred to a separatory funnel. After phase separation and removal of the organic layer, the aqueous layer was washed with cold EtOAc (2 x 50 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 50:50 as eluent affording the corresponding 3diazodihydrofuran-2(3H)-one (3m) as a bright yellow crystalline solid (0.32 g, 2.8 mmol, 30%). ¹H NMR (400 MHz, CDCl₃) δ 4.38 (t, J = 8.0 Hz, 2H, CH₂), 3.36 (t, J = 8.0 Hz, 2H, CH₂); ¹³C NMR (101 MHz, CDCl₃): 170.6, 65.3, 49.4, 23.1. The values of the NMR spectra are in accordance with reported literature data.¹⁵

¹⁵ E. S. Sattely, S. J. Meek, S. J. Malcolmson, R. R. Schrock and A. H. Hoveyda, J. Am. Chem. Soc. 2009, 131, 943.

Ethyl 2-diazo-6-hydroxyhexanoate (3n)



Adapted from a reported procedure,¹⁶ ethyl acetoacetate (37) (3.79 mL, 30.0 mmol, 2.00 equiv.) was added dropwise to a stirred suspension of sodium hydride (60 % dispersion in mineral oil, 900 mg, 22.5 mmol, 1.50 equiv.) in dry THF (35.7 mL) at 0 °C. After 30 min, tert-butyl(4-iodobutoxy)dimethylsilane (38) (3.88 mL, 15.0 mmol, 1.00 equiv.) was added slowly at ambient temperature, and the reaction was refluxed for 24 h. Saturated aqueous NH₄Cl (50 mL) was added, the two layers were separated, and the aqueous layer was extracted with diethyl ether (3 × 50 mL). The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc/pentane 5:95 as eluent to afford ethyl 2-acetyl-6-((tert-butyldimethylsilyl)oxy)hexanoate (39) as a colorless oil (3.66 g, 11.6 mmol, 77%). R_f = 0.30 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 4.19 (q, J = 7.1 Hz, 2H, OCH₂CH₃), 3.59 (t, J = 6.3 Hz, 2H, CH₂OTBS), 3.40 (t, J = 7.4 Hz, 1H, C(O)CHC(O)), 2.22 (s, 3H, C(O)CH₃), 1.95 – 1.76 (m, 2H, CHCH₂), 1.57 – 1.48 (m, 2H, CH₂CH₂OTBS), 1.38 – 1.23 (m, 5H, OCH₂CH₃ and CH₂CH₂CH), 0.88 (s, 9H, Si-tBu), 0.03 (s, 6H, 2 x Si-CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 203.4, 170.0, 62.9, 61.5, 60.1, 32.6, 28.9, 28.2, 26.1, 24.0, 18.5, 14.3, -5.2; IR (v_{max}, cm⁻¹) 2954 (m), 2930 (m), 2857 (m), 1741 (m), 1716 (s), 1360 (m), 1251 (m), 1150 (m), 1097 (s), 835 (s), 774 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd for C₁₆H₃₂NaO₄Si⁺ 339.1962; Found 339.1961.


To a solution of ethyl 2-acetyl-6-((*tert*-butyldimethylsilyl)oxy)hexanoate (**39**) (3.17 g, 10.0 mmol, 1.00 equiv.) in THF (20 mL) was added TBAF (11.0 mL, 11.0 mmol, 1.10 equiv., 1.0 M in THF) slowly and the mixture was stirred overnight at room temperature. After this time, the reaction was quechend by a saturated aqueous NH₄Cl solution (20 mL) and diluted with diethyl ether (20 mL). The aqueous layer was extracted with diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by flash column chromatography using EtOAc/pentane 50:50 as eluent to afford ethyl 2-acetyl-6-hydroxyhexanoate (**40**) as a colorless oil (1.51 g, 7.49 mmol, 75%). R_f = 0.35 (EtOAc/pentane 50:50); ¹H NMR (400 MHz, CDCl₃) δ 4.20 (qd, *J* = 7.1, 0.9 Hz, 2H, OCH₂CH₃), 3.64 (t, *J* = 6.4 Hz, 2H, CH₂OH), 3.42 (t, *J* = 7.3 Hz, 1H, C(O)CHC(O)), 2.23 (s, 3H, C(O)CH₃), 1.93 – 1.80 (m, 2H, CHCH₂), 1.64 – 1.53 (m, 3H, CH₂CH₂OH and OH), 1.42 – 1.31 (m, 2H, CH₂CH₂CH), 1.27 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 203.3, 170.0, 62.5, 61.5, 59.9, 32.4, 29.0, 27.9, 23.8, 14.3; IR (v_{max}, cm⁻¹) 3436 (w), 2938 (m), 2869 (w), 1736 (s), 1711 (s), 1361 (m), 1201 (s), 1149 (s), 1056 (m), 1032 (s); HRMS (ESI/QTOF) m/z: [M+Na]⁺ Calcd for C₁₀H₁₈NaO₄⁺ 225.1097; Found 225.1101.

Adapted from a reported procedure,¹⁶ a 1.0 M solution of tosylazide (2.07 g, 10.5 mmol, 1.50 equiv.) in MeCN (10.5 mL) was added dropwise to a solution of 2-acetyl-6-hydroxyhexanoate (**40**) (1.46 g, 7.00 mmol, 1.00 equiv.) and triethylamine (1.46 mL, 10.5 mmol, 1.50 equiv.) in MeCN (21.2 mL) at ambient temperature. After stirring for 12 h, a solution of LiOH (0.84 g, 35 mmol, 5.0 equiv.) in water (12.7 mL) was added and the mixture was stirred for another 12 h. Brine was added, the two layers were separated, and the aqueous layer was extracted with Et_2O (3 × 30 mL). The combined organic layers were washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography using EtOAc/pentane 25:75 as eluent to afford ethyl 2-diazo-6-hydroxyhexanoate (**3n**) as a bright yellow oil (0.95 g, 5.1 mmol, 73%). $R_f = 0.31$ (EtOAc/pentane 25:75); ¹H NMR (400 MHz, CDCl₃) δ 4.21 (q, J = 7.1 Hz, 2H, OCH₂CH₃), 3.77 – 3.61 (m, 2H, CH₂OH), 2.43

¹⁶ S.-F. Zhu, X.-G. Song, Y. Li, Y. Cai and Q.-L. Zhou, J. Am. Chem. Soc. **2010**, 132, 16374.

-2.30 (m, 2H, CH₂CN₂), 1.69 -1.54 (m, 4H, CH₂CH₂), 1.51 (br s, 1H, OH), 1.27 (t, J = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 62.5, 60.9, 31.7, 24.2, 23.1, 14.7; IR (v_{max}, cm⁻¹) 3437 (w), 2939 (w), 2868 (w), 2079 (s), 1686 (s), 1371 (s), 1328 (m), 1305 (s), 1276 (m), 1171 (s), 1119 (s), 1057 (m), 1024 (m), 740 (s); HRMS (APPI/LTQ-Orbitrap) m/z: [M-N₂]⁺ Calcd. for C₈H₁₄O₃⁺ 158.0937; Found 158.0937. One carbon was not resolved at 101 MHz.

1,4-Dichloro-2-(1-diazo-2,2,2-trifluoroethyl)benzene (30)




Following a modified reported procedure,¹⁷ a solution of 1,4-dichlorobenzene (**41**) (10.0 g, 68.0 mmol, 1.00 equiv.) in anhydrous THF (150 mL) was cooled to -78 °C. Then, a 2.5 M solution of *n*-butyllithium (30.0 mL, 74.8 mmol, 1.10 equiv.) in hexanes was added dropwise. The mixture was stirred for 1 h, followed by the dropwise addition of methyl 2,2,2-trifluoroacetate (**42**) (7.66 mL, 76.0 mmol, 1.12 equiv.) in 30 min. The mixture was allowed to warm up to 0 °C, stirred for 2 h and then quenched with saturated aqueous ammonium chloride solution (50 mL). Diethyl ether (50 mL) was added and the layers were separated. The aqueous layer was extracted with diethyl ether (50 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO₄, filtrated and concentrated under reduced pressure. The residue was purified by Kugelrohr distillation to afford 1-(2,5-dichloro-phenyl)-2,2,2-trifluoroethanone (**43**) as a colorless oil (12.2 g, 50.4 mmol, 74%). ¹H NMR (400 MHz, CDCl₃): δ 7.67 (s, 1H, ArH), 7.49 – 7.54 (m, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 180.8 (q, *J* = 37.6 Hz), 134.0, 133.1, 132.7, 132.1, 131.8, 129.6 (q, *J* = 2.2 Hz), 115.5 (q, *J* = 287.3 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ - 73.4. The values of the NMR spectra are in accordance with reported literature data.¹⁷

Adapted from a reported procedure,¹⁸ 1-(2,5-dichlorophenyl)-2,2,2-trifluoroethanone (**43**) (7.29 g, 30.0 mmol, 1.05 equiv.) was added to EtOH (19 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (5.32 g, 28.6 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid. Then, pentane (200 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.

Adapted from a reported procedure,¹⁸ N'-(1-(2,5-dichlorophenyl)-2,2,2-trifluoroethylidene)-4methylbenzenesulfonohydrazide (**44**) was disolved in a 0.4 M solution of potassium hydroxide (3.37 g, 60.0 mmol, 2.00 equiv.) in MeOH (17.5 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (20 mL). The product was extracted with Et₂O (3 x 30 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using pentane as eluent to afford 1,4-dichloro-2-(1-diazo-2,2,2-trifluoroethyl)benzene (**30**) as a orange oil (1.69 g, 6.09 mmol, 20%). The compound was kept as a 0.6 M solution in DCM at -18 °C. R_f = 0.95 (pentane); ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.36 (m, 2H, ArH), 7.30 – 7.25 (m, 1H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 133.7, 132.0, 131.8, 129.8, 129.5, 125.7 (q, *J* = 269.5 Hz), 123.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -56.8; IR (v_{max}, cm⁻¹) 2096 (s), 1583 (m), 1470 (m), 1320 (s), 1251 (m), 1176 (s), 1149 (s), 1107 (s), 1060 (m), 977 (s), 815 (m), 795 (m), 729 (m); HRMS (APPI/LTQ-Orbitrap) m/z: [M]⁺ Calcd. for C₈H₃Cl₂F₃⁺ 225.9558; Found 225.9565. One carbon was not resolved at 101 MHz.

¹⁷ A. S. Golubev, A. F. Shidlovskii, A. S. Peregudov and N. D. Kagramanov, *Russ Chem Bull.* **2014**, *63*, 2264.


1-(1-Diazo-2,2,2-trifluoroethyl)-3-(trifluoromethyl)benzene (3p)



2,2,2-Trifluoro-1-(3-(trifluoromethyl)phenyl)ethanone (**45**) (0.605 g, 2.50 mmol, 1.05 equiv.) was added to EtOH (4.7 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (0.443 g, 2.38 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid. Then, pentane (100 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.

procedure,¹⁸ Adapted from reported 4-methyl-N'-(2,2,2-trifluoro-1а (3(trifluoromethyl)phenyl)ethylidene)benzenesulfonohydrazide (46) was disolved in a 0.4 M solution of potassium hydroxide (281 mg, 5.00 mmol, 2.00 equiv.) in MeOH (6.25 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (15 mL). The crude product was extracted with pentane (3 x 20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using EtOAc/pentane 1:99 as eluent to afford 1-(1-diazo-2,2,2trifluoroethyl)-3-(trifluoromethyl)benzene (**3p**) as a volatile orange oil (233 mg, 0.834 mmol, 33%, contains 10 wt. % of eluent). The compound was kept as a 0.6 M solution in DCM at -18 °C. R_f = 0.95 (EtOAc/pentane 1:99); ¹H NMR (400 MHz, CDCl₃) δ 7.53 (tt, J = 7.8, 0.8 Hz, 1H, ArH), 7.49 – 7.41 (m, 1H, ArH), 7.33 – 7.23 (m, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 132.2 (q, J = 32.6 Hz), 130.1, 125.3, 125.3 (q, J = 269.6 Hz), 125.2, 123.8 (q, J = 272.5 Hz), 122.7 (q, J = 3.8 Hz), 118.9 – 118.6 (m); ¹⁹F NMR (376 MHz, CDCl₃) δ -57.4, -63.1; IR (v_{max}, cm⁻¹) 2089 (s), 1616 (w), 1591 (w), 1496 (w), 1455 (m), 1362 (m), 1338 (s), 1312 (s), 1273 (m), 1168 (s), 1111 (s), 1076 (s), 977 (m), 795 (s), 692 (s); HRMS (ESI/QTOF) $m/z: [M-N_2+H]^+$ Calcd. for C₉H₅F₆⁺ 227.0290; Found 227.0291. One carbon was not resolved at 101 MHz.

4-(1-Diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (3q)



A solution of 4-bromo-biphenyl (47) (4.66 g, 20.0 mmol, 1.00 equiv.) in anhydrous THF (100 mL) was cooled to -78 °C. Then, a 2.5 M solution of *n*-butyllithium (9.60 mL, 24.0 mmol, 1.20 equiv.) in hexanes was added dropwise. The mixture was stirred for 1 h, followed by the dropwise addition of methyl 2,2,2-trifluoroacetate (42) (2.21 mL, 22.0 mmol, 1.10 equiv.) in 30 min. The mixture was allowed to warm up to room temperature, stirred for 18 h and then quenched with saturated aqueous ammonium chloride solution (50 mL). Diethyl ether (50 mL) was added and the layers were separated. The aqueous layer was extracted with diethyl ether (2 x 25 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO₄, filtrated and concentrated under reduced pressure. The residue was


¹⁸ E. Emer, J. Twilton, M. Tredwell, S. Calderwood, T. L. Collier, B. Liégault, M. Taillefer and V. Gouverneur, *Org. Lett.* **2014**, *16*, 6004.

purified by silica gel chromatography using pentane/EtOAc 90:10 as eluent to afford 1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethanone (**48**) as a slight yellow oil (3.37 g, 13.5 mmol, 67%). ¹H NMR (400 MHz, CDCl₃) δ 8.20 – 8.10 (m, 2H, Ar*H*), 7.81 – 7.74 (m, 2H, Ar*H*), 7.68 – 7.62 (m, 2H, Ar*H*), 7.54 – 7.41 (m, 3H, Ar*H*); ¹³C NMR (101 MHz, CDCl₃) δ 180.3 (q, *J* = 34.8 Hz), 148.4, 139.3, 130.9 (q, *J* = 2.2 Hz), 129.3, 129.1, 128.7, 127.8, 127.5, 116.9 (q, *J* = 291.4 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -71.32. The values of the NMR spectra are in accordance with reported literature data.¹⁸

Following a reported procedure,¹⁸ 1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethanone (**48**) (3.36 g, 13.5 mmol, 1.05 equiv.) was added to EtOH (9 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (2.40 g, 12.9 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid. Then, pentane (200 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.

procedure,¹⁸ Following а reported N'-(1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethylidene)-4methylbenzenesulfonohydrazide (49) was disolved in a 0.4 M solution of potassium hydroxide (3.37 g, 60.0 mmol, 2.00 equiv.) in MeOH (17.5 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (20 mL). The product was extracted with Et₂O (3 x 30 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using pentane as eluent to afford 4-(1-Diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (3q) as a red solid (1.42 g, 5.44 mmol, 50%). The compound was kept at -18 °C. R_f = 0.70 (pentane); ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.62 (m, 2H, ArH), 7.62 – 7.55 (m, 2H, ArH), 7.45 (dd, J = 8.4, 6.9 Hz, 2H, ArH), 7.41 – 7.34 (m, 1H, ArH), 7.17 (d, J = 8.2 Hz, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 140.2, 139.0, 129.1, 128.2, 127.7, 127.0, 125.8 (q, J = 269.6 Hz), 122.7, 122.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -57.32. One carbon was not resolved at 101 MHz. The values of the NMR spectra are in accordance with reported literature data.¹⁸

1-Bromo-4-(1-diazo-2,2,2-trifluoroethyl)benzene (3r)




1-(4-Bromophenyl)-2,2,2-trifluoroethanone (**50**) (633 mg, 2.50 mmol, 1.05 equiv.) was added to EtOH (4.7 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (0.443 g, 2.38 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid. Then, pentane (100 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.

Following a reported procedure,¹⁸ N'-(1-(4-bromophenyl)-2,2,2-trifluoroethylidene)-4methylbenzenesulfonohydrazide (**51**) was disolved in a 0.4 M solution of potassium hydroxide (281 mg, 5.00 mmol, 2.00 equiv.) in MeOH (12.5 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (15 mL). The crude product was extracted with pentane (3 x 20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using pentane as eluent to afford 1-bromo-4-(1-diazo-2,2,2-trifluoroethyl)benzene (**3r**) as a orange oil (146 mg, 0.551 mmol, 22%). The compound was kept as a 0.6 M solution in DCM at -18 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.56 – 7.48 (m, 2H, ArH), 7.01 – 6.91 (m, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 132.8, 125.7 (q, J = 270.3 Hz), 124.0, 123.0, 119.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -57.5. One carbon was not resolved at 101 MHz. The values of the NMR spectra are in accordance with reported literature data.¹⁸


6. Preparation of EBX reagents

1,1,1,3,3,3-Hexafluoro-2-(2-iodophenyl)propan-2-ol (11)



Following a reported procedure,¹⁹ TMEDA (1.27 mL, 8.40 mmol, 0.20 equiv.) was added to a solution of *n*-BuLi (37.0 mL, 92.0 mmol, 2.20 equiv., 2.5 M in hexanes). After 15 min, the cloudy solution was cooled to 0 °C and 1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-ol (**52**) (7.07 mL, 42.0 mmol, 1.00 equiv.) in THF (6.0 mL) was added dropwise. The reaction was stirred 30 min at 0 °C and then 18 h at room temperature. Then, THF (30.0 mL) was added, followed by the portionwise addition of I₂ (11.3 g, 44.5 mmol, 1.05 equiv.) at 0 °C and the mixture was stirred at 0 °C for 30 min and 4 h at room temperature. The reaction was quenched with saturated aqueous NH₄Cl (50 mL) and extracted with diethyl ether (3 x 30 mL). The combined organic phases were washed with water, brine, dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 3:97 as eluent to afford 1,1,1,3,3,3-hexafluoro-2-(2-iodophenyl)propan-2-ol (**11**) as a colorless oil (13.9 g, 37.5 mmol, 89%). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (dd, *J* = 7.9, 1.4 Hz, 1H, Ar*H*), 7.63 (d, *J* = 8.2 Hz, 1H, Ar*H*), 7.43 (dt, *J* = 8.4, 1.4 Hz, 1H, Ar*H*), 7.11 (dt, *J* = 8.0, 1.5 Hz, 1H, Ar*H*), 4.23 (s, 1H, O*H*); ¹³C NMR (101 MHz, CDCl₃) δ 144.7, 131.4, 130.0, 129.7, 128.0, 122.6 (q, *J* = 291.4 Hz), 90.6, 78.9 (q, *J* = 32.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -73.4. The values of the NMR spectra are in accordance with reported literature data.¹⁹

3,3-Bis(trifluoromethyl)-1λ³-benzo[d][1,2]iodaoxol-1(3H)-yl acetate (53)




Following a slightly modified procedure,²⁰ a 500 mL flsak was charged with glacial acetic acid (188 mL), 1,1,1,3,3,3-hexafluoro-2-(2-iodophenyl)propan-2-ol (**11**) (13.9 g, 37.5 mmol, 1.00 equiv.) and cobalt(II) chloride hexahydrate (89.0 g, 0.375 mmol, 0.01 equiv.). The reaction vessel was purged with O₂ for 5 min before acetaldehyde (21.4 mL, 379 mmol, 10.0 equiv.) was added in one portion. The reaction mixture was stirred under 1 atm of O₂, delivered by inflated balloon, at room temperature for 12 h. Acetaldehyde (21.4 mL, 379 mmol, 10.00 equiv.) was added and the reaction continue for 6 h. The solvent was removed under reduced pressure and the residue was dissolved in DCM. The organic layer was washed with distilled water (50 mL) and extracted with DCM (3 x 50 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The obtained residue was triturated in pentane for 0.5 h, filtered and washed with pentane (operation repeated 2 times) to afford 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) as a white solid (9.91 g, 23.2 mmol, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (ddd, *J* = 8.4, 7.1, 1.6 Hz, 1H, Ar*H*), 7.85 – 7.69 (m, 3H, Ar*H*), 2.19 (s, 3H, (O)CC*H*₃); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 174.4, 134.2, 131.4, 131.0, 130.8, 129.5 – 129.0 (m), 123.1 (q, *J* = 289.5 Hz), 116.1, 84.5 – 83.7 (m), 20.0; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -75.1. The values of the NMR spectra are in accordance with reported literature data.²¹

¹⁹ J. Cvengroš, D. Stolz and A. Togni, *Synthesis* **2009**, 2818.

²⁰ A. Maity, S.-M. Hyun and D. C. Powers, *Nat. Chem.* **2018**, *10*, 200.

²¹ P. Eisenberger, S. Gischig and A. Togni, *Chem. Eur J.* **2006**, *12*, 2579.


Tert-butyldiphenyl((6-(trimethylsilyl)hex-5-yn-1-yl)oxy)silane (56g)



Following a reported procedure,²² butyllithium (17.6 mL, 44.0 mmol, 2.20 equiv., 2.5 M in hexanes) was added dropwise to a stirring solution of 5-hexyn-1-ol (**54**) (2.20 mL, 20.0 mmol, 1.00 equiv.) in THF (40.0 mL) at -78 °C. Stirring was continued for 1 h, then chlorotrimethylsilane (5.58 mL, 44.0 mmol, 2.20 equiv.) was added at -78 °C. After 1 h, the reaction mixture was warmed to 0 °C. Aqueous 1M HCl (30 mL) was added dropwise and stirring was continued for 30 min at room temperature. The reaction mixture was extracted with diethyl ether (2 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (10 mL), dried over anhydrous MgSO₄, filtered and the solvent was removed under reduced pressure. The crude oil was purified by column chromatography using Et₂O/pentane 20:80 as eluent to afford 6-(trimethylsilyl)hex-5-yn-1-ol (**55**) as a colorless oil (2.12 g, 14.2 mmol, 71%). ¹H NMR (400 MHz, CDCl₃) δ 3.73 – 3.62 (m, 2H, CH₂OH), 2.27 (t, *J* = 6.8 Hz, 2H, C≡CCH₂), 1.80 – 1.52 (m, 4H, CH₂CH₂), 1.13 (br s, 1H, OH), 0.14 (s, 9H, TMS); ¹³C NMR (101 MHz, CDCl₃) δ 107.3, 84.9, 62.6, 32.0, 25.0, 19.8, 0.3. The values of the NMR spectra are in accordance with reported literature data.²²

Following a reported procedure,²³ under an atmosphere of nitrogen, 6-(trimethylsilyl)hex-5-yn-1-ol (**55**) (511 mg, 3.00 mmol, 1.00 equiv.) was dissolved in DCM (10.00 mL). The alcohol was then treated, in succession, with imidazole (306 mg, 4.50 mmol, 1.50 equiv.), DMAP (110 mg, 0.900 mmol, 0.3 equiv.), and *tert*-butylchlorodiphenylsilane (1.17 mL, 4.50 mmol, 1.50 equiv.). The reaction was stirred at room temperature. After 1 hour, the reaction was diluted with 30 mL of water then extracted with DCM (2 x 30 mL). The combined organic extracts were dried over anhydrous MgSO₄, filtered, and the solvent was removed under reduced pressure. The crude oil was purified by column chromatography using EtOAc/pentane 2:98 as eluent to afford tert-butyldiphenyl((6-(trimethylsilyl)hex-5-yn-1-yl)oxy)silane (**56g**) as a colorless oil (1.21 g, 2.95 mmol, 98%). ¹H NMR (400 MHz, CDCl₃) δ 7.70 - 7.62 (m, 4H, ArH), 7.45 - 7.34 (m, 6H, ArH), 3.67 (t, *J* = 5.9 Hz, 2H, CH₂O), 2.23 (t, *J* = 6.6 Hz, 2H, C≡CCH₂), 1.72 - 1.56 (m, 4H, CH₂CH₂), 1.05 (s, 9H, tBu), 0.14 (s, 9H, TMS); ¹³C NMR (101 MHz, CDCl₃) δ 135.7, 134.2, 129.7, 127.8, 107.6, 84.6, 63.6, 31.8, 27.0, 25.3, 19.8, 19.4, 0.3. The values of the NMR spectra are in accordance with reported literature data.²³

2-(6-(Trimethylsilyl)hex-5-yn-1-yl)isoindoline-1,3-dione (56k)




To a stirring solution of 6-(trimethylsilyl)hex-5-yn-1-ol (**55**) (852 mg, 5.00 mmol, 1.00 equiv.) in THF (16.7 mL) was added triphenylphosphine (1.44 g, 5.50 mmol, 1.10 equiv.) and DIAD (1.15 mL, 5.50 mmol, 1.10 equiv.) at 0 °C. The reaction mixture was stirred at this temperature for 15 min and then, phthalimide (**57**) (750 mg, 5.10 mmol, 1.02 equiv.) was added. The reaction was continued at room temperature for 5 h, then cold water (20 mL) was added and the product was extracted with EtOAc (3 x 40 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous MgSO₄ and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using Et₂O/pentane 10:90 as eluent to furnish 2-(6-(trimethylsilyl)hex-5-yn-1-yl)isoindoline-1,3-dione (**56k**) as a white solid (1.37 g, 4.58 mmol, 92%). M.p. 68-70 °C; R_f = 0.26

²² M. Gersch, F. Gut, V. S. Korotkov, J. Lehmann, T. Böttcher, M. Rusch, C. Hedberg, H. Waldmann, G. Klebe and S. A. Sieber, *Angew. Chem. Int. Ed.* **2013**, *52*, 3009.

²³ E. C. McLaughlin and M. P. Doyle, *J. Org. Chem.* **2008**, *73*, 4317.


(Et₂O/pentane 10:90); ¹H NMR (400 MHz, CDCl₃) δ 7.83 (dd, J = 5.4, 3.1 Hz, 2H, ArH), 7.70 (dd, J = 5.4, 3.1 Hz, 2H, ArH), 3.70 (t, J = 7.0 Hz, 2H, CH₂NPhth), 2.27 (t, J = 7.1 Hz, 2H, C=CCH₂), 1.85 - 1.74 (m, 2H, CH₂), 1.61 - 1.49 (m, 2H, CH₂), 0.12 (s, 9H, TMS); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 134.0, 132.3, 123.3, 106.7, 85.1, 37.6, 27.8, 25.9, 19.6, 0.3; IR (v_{max}, cm⁻¹) 2955 (w), 2931 (w), 2170 (w), 1770 (w), 1705 (m), 1440 (w), 1390 (s), 1352 (m), 1324 (m), 1247 (m), 1035 (m), 904 (m), 841 (s), 761 (s), 718 (s), 638 (m); HRMS (ESI/QTOF) m/z: [M+H]⁺ Calcd. for C₁₇H₂₂NO₂Si⁺ 300.1414; Found 300.1413.

General procedure C: Synthesis of EBX reagents:



To a solution of 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (1.00 equiv.) in dry DCM (*c* = 0.2 M) was added trimethylsilyl trifluoromethanesulfonate (1.10 equiv.) dropwise at room temperature and the reaction mixture was stirred for 1 h. After this time, the corresponding trimethylethynylsilane (**56a** – **56k**) (1.10 equiv.) was added and the mixture was stirred for 6 h at room temperature. The reaction mixture was then quenched with saturated aqueous NaHCO₃ solution and extracted with dichloromethane (3 times). The combined organic extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc/pentane as eluent to give the corresponding EBX reagent (**2a** – **2k**).


$((3,3-Bis(trifluoromethyl)-1\lambda^3-benzo[d][1,2]iodaoxol-1(3H)-yl)ethynyl)triisopropylsilane (2a)$



2a

Following general procedure C, starting from triisopropyl((trimethylsilyl)ethynyl)silane (**56a**) (2.80 g, 11.0 mmol) and 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (4.28 g, 10.0 mmol), afforded ((3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)ethynyl)triisopropylsilane (**2a**) as a white solid (5.33 g, 9.68 mmol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 8.36 (dd, *J* = 7.9, 1.5 Hz, 1H, Ar*H*), 7.88 – 7.81 (m, 1H, Ar*H*), 7.74 – 7.62 (m, 2H, Ar*H*), 1.23 – 1.07 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 132.9, 131.3, 130.1, 130.2 – 130.0 (m), 128.3, 123.7 (q, *J* = 290.4 Hz), 112.3, 111.0, 81.6 (p, *J* = 29.5 Hz), 69.9, 18.7, 11.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁴


1-(5-Chloropent-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzo[*d*][1,2]iodaoxole (2b)



²⁴ Y. Li, J. P. Brand and J. Waser, *Angew. Chem. Int. Ed.* **2013**, *52*, 6743.


benzo[*d*][1,2]iodaoxole (**2b**) as a white solid (273 mg, 0.580 mmol, 58%). M.p. 113-115 °C; $R_f = 0.47$ (EtOAc/pentane 15:85); ¹H NMR (400 MHz, CDCl₃) δ 8.25 – 8.17 (m, 1H, Ar*H*), 7.87 – 7.78 (m, 1H, Ar*H*), 7.73 – 7.64 (m, 2H, Ar*H*), 3.70 (t, *J* = 6.1 Hz, 2H, *CH*₂Cl), 2.74 (t, *J* = 6.9 Hz, 2H, *CH*₂C≡C), 2.07 (p, *J* = 6.6 Hz, 2H, *CH*₂CH₂Cl); ¹³C NMR (101 MHz, CDCl₃) δ 133.0, 131.3, 130.1, 130.1 – 129.9 (m), 128.3, 123.7 (q, *J* = 290.5 Hz), 111.0, 105.5, 81.7 (p, *J* = 29.6 Hz), 45.2, 43.5, 31.0, 17.8; ¹⁹F NMR (376 MHz, CDCl₃) δ - 76.2; IR (v_{max}, cm⁻¹) 2158 (w), 1441 (w), 1427 (w), 1263 (s), 1178 (s), 1145 (s), 966 (s), 946 (s), 768 (s), 753 (s), 729 (s), 660 (m); HRMS (ESI/QTOF) m/z: [M+H]⁺ Calcd. for C₁₄H₁₁ClF₆IO⁺ 470.9442; Found 470.9446.

1-(Hex-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzo[d][1,2]iodaoxole (2c)



Following general procedure C, starting from hex-1-yn-1-yltrimethylsilane (**56c**) (222 µL, 1.10 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-(hex-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2c**) as a white solid (285 mg, 0.630 mmol, 63%). ¹H NMR (400 MHz, CDCl₃) δ 8.26 – 8.18 (m, 1H, Ar*H*), 7.86 – 7.79 (m, 1H, Ar*H*), 7.73 – 7.64 (m, 2H, Ar*H*), 2.53 (t, *J* = 7.0 Hz, 2H, CH₂C≡C), 1.67 – 1.56 (m, 2H, CH₂CH₂C≡C), 1.53 – 1.42 (m, 2H, CH₂CH₃), 0.96 (t, *J* = 7.3 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 132.9, 131.2, 130.2, 130.0 – 129.8 (m), 128.3, 123.8 (q, *J* = 290.7 Hz), 111.1, 108.1, 81.7 (p, *J* = 29.4 Hz), 43.5, 30.6, 22.2, 20.2, 13.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁵

1-(Cyclopropylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodaoxole (2d)




2d

Following general procedure C, starting from (cyclopropylethynyl)trimethylsilane (**56d**) (995 μ L, 5.50 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (2.14 g, 5.00 mmol), afforded 1-(cyclopropylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2d**) as an off-white solid (873 mg, 2.01 mmol, 40%). ¹H NMR (400 MHz, CDCl₃) δ 8.32 – 8.14 (m, 1H, Ar*H*), 7.88 – 7.74 (m, 1H, Ar*H*), 7.74 – 7.59 (m, 2H, Ar*H*), 1.54 (tt, J = 8.2, 5.0 Hz, 1H, C*H*C=C), 1.00 – 0.91 (m, 2H, C*H*₂-cyclopropyl), 0.91 – 0.85 (m, 2H, C*H*₂-cyclopropyl); ¹³C NMR (101 MHz, CDCl₃) δ 132.9, 131.2, 130.2, 130.0, 129.8, 128.2, 123.8 (q, *J* = 290.8 Hz), 81.7 (p, *J* = 29.5 Hz), 39.4, 9.5, 1.0; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.3. The values of the NMR spectra are in accordance with reported literature data.²⁶

²⁵ X. Li, X. Xie, N. Sun and Y. Liu, *Angew. Chem. Int. Ed.* **2017**, *56*, 6994.


²⁶ J. Wu, X. Deng, H. Hirao and N. Yoshikai, J. Am. Chem. Soc. **2016**, 138, 9105.

1-(Cyclohex-1-en-1-ylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodaoxole (2e)




Following general procedure C, starting from (cyclohex-1-en-1-ylethynyl)trimethylsilane (**56e**) (196 mg, 1.10 mmol) and 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-(cyclohex-1-en-1-ylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[*d*][1,2]iodaoxole (**2e**) as an off-white solid (213 mg, 0.450 mmol, 45%). ¹H NMR (400 MHz, CDCl₃) δ 8.29 – 8.13 (m, 1H, Ar*H*), 7.91 – 7.78 (m, 1H, Ar*H*), 7.73 – 7.60 (m, 2H, Ar*H*), 6.36 (p, *J* = 2.2 Hz, 1H, C=C*H*), 2.28 – 2.13 (m, 4H, 2 x CH₂C=C), 1.75 – 1.54 (m, 4H, CH₂CH₂); ¹³C NMR (101 MHz, CDCl₃) δ 140.1, 132.9, 129.8, 129.6, 128.1, 127.8, 123.4 (q, *J* = 290.3 Hz), 119.8, 111.2, 107.7, 81.3 (p, *J* = 29.6 Hz), 50.5, 28.7, 25.7, 21.9, 20.9; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁷

1-((2-Bromophenyl)ethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzo[d][1,2]iodaoxole (2f)



Following general procedure C, starting from ((2-bromophenyl)ethynyl)trimethylsilane (**56f**) (234 μ L, 1.10 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-((2-bromophenyl)ethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2f**) as a white solid (535 mg, 0.970 mmol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 8.52 - 8.43 (m, 1H, Ar*H*), 7.90 - 7.81 (m, 1H, Ar*H*), 7.76 - 7.68 (m, 2H, Ar*H*), 7.66 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar*H*), 7.57 (dd, *J* = 7.6, 1.8 Hz, 1H, Ar*H*), 7.35 (td, *J* = 7.6, 1.3 Hz, 1H, Ar*H*), 7.32 - 7.24 (m, 1H, Ar*H*); ¹³C NMR (101 MHz, CDCl₃) δ 134.5, 133.2, 132.9, 131.4, 131.2, 130.2 - 129.9 (m), 130.0, 128.9, 127.5, 126.2, 123.9, 123.7 (q, *J* = 290.6 Hz), 111.6, 103.0, 81.8 (p, *J* = 29.8 Hz), 59.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.1. The values of the NMR spectra are in accordance with reported literature data.²⁸

((6-(3,3-Bis(trifluoromethyl)- $1\lambda^3$ -benzo[d][1,2]iodaoxol-1(3H)-yl)hex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane (2g)




Following general procedure C, starting from tert-butyldiphenyl((6-(trimethylsilyl)hex-5-yn-1-yl)oxy)silane (**56g**) (450 mg, 1.10 mmol) and 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[d][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded ((6-(3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[d][1,2]iodaoxol-

²⁷ V. V. Zhdankin, C. J. Kuehl, A. P. Krasutsky, J. T. Bolz and A. J. Simonsen, J. Org. Chem. **1996**, *61*, 6547.

²⁸ Y. Yang, P. Antoni, M. Zimmer, K. Sekine, F. F. Mulks, L. Hu, L. Zhang, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Angew. Chem. Int. Ed.* **2019**, *58*, 5129.

1(3H)-yl)hex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane (**2g**) as a white solid (355 mg, 0.500 mmol, 50%). M.p. 110-112 °C; R_f = 0.40 (EtOAc/pentane 10:90); ¹H NMR (400 MHz, CDCl₃) δ 8.21 (dd, *J* = 8.1, 1.3 Hz, 1H, Ar*H*), 7.86 -7.78 (m, 1H, Ar*H*), 7.72 - 7.58 (m, 6H, Ar*H*), 7.46 - 7.32 (m, 6H, Ar*H*), 3.77 - 3.66 (m, 2H, C*H*₂OTBDPS), 2.59 - 2.49 (m, 2H, C*H*₂C≡C), 1.80 - 1.65 (m, 4H, C*H*₂C*H*₂O), 1.06 (s, 9H, *tBu*-Si); ¹³C NMR (101 MHz, CDCl₃) δ 135.6, 133.8, 132.7, 131.1, 130.0, 129.9 - 129.7 (m), 129.7, 128.1, 127.7, 123.6 (q, *J* = 290.4 Hz), 110.9, 107.7, 81.5 (p, *J* = 29.5 Hz), 63.2, 43.7, 31.6, 26.9, 25.0, 20.2, 19.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2; IR (v_{max}, cm⁻¹) 2934 (w), 2855 (w), 2155 (w), 2071 (m), 1695 (w), 1427 (m), 1266 (m), 1257 (m), 1181 (s), 1151 (s), 1107 (m), 966 (s), 946 (s), 762 (s), 732 (s), 701 (s); HRMS (ESI/QTOF) m/z: [M+H]⁺ Calcd. for C₃₁H₃₂F₆lO₂Si⁺ 705.1115; Found 705.1114.


1-(Phenylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzo[*d*][1,2]iodaoxole (2h)



2h

Following general procedure C, starting from trimethyl(phenylethynyl)silane (**56h**) (192 mg, 1.10 mmol) and 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[*d*][1,2]iodaoxol-1(3H)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-(phenylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[*d*][1,2]iodaoxole (**2h**) as a white solid (395 mg, 0.840 mmol, 84%). ¹H NMR (400 MHz, CDCl₃) δ 8.34 – 8.24 (m, 1H, Ar*H*), 7.86 (ddt, *J* = 7.4, 3.2, 1.4 Hz, 1H, Ar*H*), 7.75 – 7.66 (m, 2H, Ar*H*), 7.59 – 7.53 (m, 2H, Ar*H*), 7.48 – 7.37 (m, 3H, Ar*H*); ¹³C NMR (101 MHz, CDCl₃) δ 133.1, 132.8, 131.4, 130.3, 130.1, 130.0, 128.8, 128.5, 123.7 (q, *J* = 289.8 Hz), 121.4, 111.6, 105.4, 82.5 – 81.1 (m), 54.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁹


1-(Thiophen-2-ylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[*d*][1,2]iodaoxole (2i)



Following general procedure C, starting from trimethyl(thiophen-2-ylethynyl)silane (**56i**) (182 µL, 1.10 mmol) and 3,3-bis(trifluoromethyl)- $1\lambda^3$ -benzo[d][1,2]iodaoxol-1(3H)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-(thiophen-2-ylethynyl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodaoxole (**2i**) as an off-white solid (403 mg, 0.850 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 8.30 – 8.19 (m, 1H, ArH), 7.89 – 7.80 (m, 1H, ArH), 7.76 – 7.66 (m, 2H, ArH), 7.44 – 7.38 (m, 2H, ArH), 7.07 (dd, J = 5.1, 3.7 Hz, 1H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 135.2, 133.2, 131.4, 130.2, 123.0, 129.9, 128.5, 127.5, 123.7 (q, J = 291.2 Hz), 121.3, 111.8, 98.4, 81.8 (p, J = 29.7 Hz), 59.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁹


²⁹ X. Wu, S. Shirakawa and K. Maruoka, *Org. Biomol. Chem.* **2014**, *12*, 5388.

1-(3,3-Dimethylbut-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodaoxole (2j)




Following general procedure C, starting from (3,3-dimethylbut-1-yn-1-yl)trimethylsilane (**56**j) (229 µL, 1.10 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 1-(3,3-dimethylbut-1-yn-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**2**j) as a white solid (350 mg, 0.780 mmol, 78%). ¹H NMR (400 MHz, CDCl₃) δ 8.24 – 8.14 (m, 1H, Ar*H*), 7.89 – 7.78 (m, 1H, Ar*H*), 7.74 – 7.64 (m, 2H, Ar*H*), 1.34 (s, 9H, *tBu*); ¹³C NMR (101 MHz, CDCl₃) δ 132.7, 131.1, 130.3, 130.0, 128.0, 123.9 (q, *J* = 290.3 Hz), 116.1, 111.2, 81.9 (p, *J* = 29.6 Hz), 42.0, 30.8, 29.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2. The values of the NMR spectra are in accordance with reported literature data.²⁷


$2-(6-(3,3-Bis(trifluoromethyl)-1\lambda^3-benzo[d][1,2]iodaoxol-1(3H)-yl)hex-5-yn-1-yl)isoindoline-1,3-dione (2k)$





Following general procedure C, starting from 2-(6-(trimethylsilyl)hex-5-yn-1-yl)isoindoline-1,3-dione (**56k**) (330 mg, 1.10 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**53**) (428 mg, 1.00 mmol), afforded 2-(6-(3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)hex-5-yn-1-yl)isoindoline-1,3-dione (**2k**) as a white solid (590 mg, 0.990 mmol, 99%). M.p. 139-141 °C; R_f = 0.13 (EtOAc/pentane 15:85); ¹H NMR (400 MHz, CDCl₃) δ 8.22 – 8.15 (m, 1H, Ar*H*), 7.89 – 7.78 (m, 3H, Ar*H*), 7.77 – 7.65 (m, 4H, Ar*H*), 3.75 (t, *J* = 7.0 Hz, 2H, *CH*₂CH₂C); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 134.2, 133.0, 132.2, 131.2, 130.1, 130.0 – 129.8 (m), 128.4, 123.7 (q, *J* = 290.4 Hz), 123.4, 111.0, 106.9, 81.7 (p, *J* = 29.4 Hz), 44.6, 37.4, 27.8, 25.6, 20.0; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.2; IR (v_{max}, cm⁻¹) 2355 (w), 2164 (w), 2099 (w), 1707 (m), 1393 (m), 1264 (m), 1180 (s), 1154 (s), 965 (m), 947 (s), 767 (s), 751 (s), 714 (s) HRMS (ESI/QTOF) m/z: [M+H]⁺ Calcd. for C₂₃H₁₇F₆INO₃⁺ 596.0152; Found 596.0157.

7. Spectra of new compounds












¹H-NMR (400 MHz, CDCl₃) of compound **5e**










10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

$^1\text{H-NMR}$ (400 MHz, CDCl3) of compound 5g $\begin{array}{c} 4,76\\ 4,23\\ 4,23\\ 4,27\\ 4,26\\ 4,25\\ 4,26\\ 4,23\\$ $\begin{array}{c} 1.30\\ 1.28\\ 1.28\\ 1.27\\ 1.08\\ 1.08\\ 1.08\\ 1.00\\ 1.00\\ 1.00\\ 1.00\\ 1.00\\ 1.00\\ 0.98\\ 0.97\\ 0.95\\$ TIPS 5g 2.00 J ₽-96.0 12.18-21.00-4.5 4.0 f1 (ppm) -C 8.5 7.5 1.5 1.0 8.0 7.0 6.5 5.0 3.5 3.0 2.5 0.5 6.0 5.5 2.0 0.0 $^{13}\mbox{C-NMR}$ (101 MHz, $\mbox{CDCl}_3)$ of compound 5g-- 87.26 63.19 ~ 18.67 ~ 14.18 ~ 11.30 - 168.81 ő TIPS 5g 78 77 f1 (ppm) 79 76 75


210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)









¹H-NMR (400 MHz, CDCl₃) of compound 5k (first diastereoisomer)




¹³C-NMR (101 MHz, CDCl₃) of compound 5k (first diastereoisomer)







S61

















¹H-NMR (400 MHz, CDCl₃) of compound 5p





¹H-NMR (400 MHz, CDCl₃) of compound 5q







¹H-NMR (400 MHz, CDCl₃) of compound 5s







¹H-NMR (400 MHz, CDCl₃) of compound 5u













A 47 4 47

¹H-NMR (400 MHz, CDCl₃) of compound 5y





${}^{\mathbf{31}}\mathbf{P}\text{-}\mathbf{NMR}$ (162 MHz, CDCl3) of compound $\mathbf{5y}$




140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)


¹H-NMR (400 MHz, CDCl₃) of compound 5z









-60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm) 10 -10 -20 -30 0 -40 -50




$^{19}\text{F-NMR}$ (376 MHz, CDCl₃) of compound 5ab




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)






10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)


¹H-NMR (400 MHz, CDCl₃) of compound **5ad**






S85


$^{19}\mbox{F-NMR}$ (376 MHz, $\mbox{CDCI}_3\mbox)$ of compound $\mbox{5ae}$



¹H-NMR (400 MHz, CDCl₃) of compound **5af**




¹H-NMR (400 MHz, CDCl₃) of compound **5ag**




¹H-NMR (400 MHz, CDCl₃) of compound 5ai


7.2.3355



$^{19}\text{F-NMR}$ (376 MHz, CDCl3) of compound 5ai




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)




S91


 $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) of compound 5aj




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)




 $^{19}\mbox{F-NMR}$ (376 MHz, $\mbox{CDCl}_3\mbox)$ of compound \mbox{Sak}




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)




¹H-NMR (400 MHz, CDCl₃) of compound **3n**







$^{19}\text{F-NMR}$ (376 MHz, CDCl3) of compound 3o





10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)



$^{19}\text{F-NMR}$ (376 MHz, CDCl3) of compound 3p








$^{19}\mbox{F-NMR}$ (376 MHz, $\mbox{CDCl}_3\mbox)$ of compound 2b




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

¹H-NMR (400 MHz, CDCl₃) of compound **2g**




$^{19}\mbox{F-NMR}$ (376 MHz, $\mbox{CDCl}_3\mbox)$ of compound 2g




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)






 $^{19}\text{F-NMR}$ (376 MHz, CDCl3) of compound 2k




10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)




S107

¹H-NMR (400 MHz, CDCl₃) of compound **40**








S109

8. X-ray diffraction parameters and data for 5aj



| Empirical formula | $C_{23}H_{22}F_3NO$ |
|------------------------------------|---|
| Formula weight | 385.41 |
| Temperature | 140.00(10) K |
| Wavelength | 1.54184 Å |
| Crystal system | Orthorhombic |
| Space group | Pbca |
| Unit cell dimensions | a = 8.81133(9) Å α = 90°. |
| | b = 20.9653(2) Å β = 90°. |
| | c = 22.3585(3) Å γ = 90°. |
| Volume | 4130.33(8) Å ³ |
| Z | 8 |
| Density (calculated) | 1.240 Mg/m ³ |
| Absorption coefficient | 0.785 mm ⁻¹ |
| F(000) | 1616 |
| Crystal size | 0.440 x 0.151 x 0.120 mm ³ |
| Θ range for data collection | 3.954 to 72.795°. |
| Index ranges | -10 ≤ h ≤ 10, -25 ≤ k ≤ 25, -27 ≤ l ≤ 27 |
| Reflections collected | 32007 |
| Independent reflections | 4078 [<i>R</i> _{int} = 0.0354] |
| Completeness to θ = 67.684° | 99.8 % |
| Absorption correction | Gaussian |
| Max. and min. transmission | 1.000 and 0.548 |
| Refinement method | Full-matrix least-squares on F ² |
| Data / restraints / parameters | 4078 / 133 / 349 |
| Goodness-of-fit on F ² | 1.053 |
| Final R indices $[I > 2\sigma(I)]$ | $R_1 = 0.0308, wR_2 = 0.0838$ |
| R indices (all data) | $R_1 = 0.0374, wR_2 = 0.0864$ |
| Extinction coefficient | 0.00022(6) |
| Largest diff. peak and hole | 0.275 and -0.189 e.Å $^{-3}$ |
| | |